

(19) Europäisches Patentamt
 European Patent Office
 Office européen des brevets



(11) Publication number:

0 208 491 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **25.08.93** (51) Int. Cl.5: **C12N 15/62, C12P 21/02, C12N 9/28, C12N 9/54**
 (21) Application number: **86305057.1**
 (22) Date of filing: **30.06.86**

(54) **Hybrid polypeptides and process for their preparation.**

- (30) Priority: **03.07.85 US 752267**
 (43) Date of publication of application:
14.01.87 Bulletin 87/03
 (45) Publication of the grant of the patent:
25.08.93 Bulletin 93/34
 (84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE
 (56) References cited:

THE EMBO JOURNAL, vol. 4, no. 6, 26th June 1985, pages 1583-1587, IRL Press Ltd, Oxford, GB; J. TOMMASSEN et al.: "Localization of functional domains in *E. coli* K-12 outer membrane porins"

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, vol. 78, no. 4, April 1981, pages 2169-2173, Washington, D.C., US; W.P.

SCHNEIDER et al.: "Procedure for production of hybrid genes and proteins and its use in assessing significance of amino acid differences in homologous tryptophan synthetase alpha polypeptides"

- (73) Proprietor: **GENENCOR INTERNATIONAL, INC.**
180 Kimball Way
South San Francisco, CA 94080(US)
 (72) Inventor: **Gray, Gregory L.**
530 Elm Court
South San Francisco California 94080(US)
 (74) Representative: **Allard, Susan Joyce et al**
BOULT, WADE & TENNANT, 27 Furnival Street
London EC4A 1PQ (GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

NUCLEIC ACIDS RESEARCH, vol. 11, no. 16,
25th August 1983, pages 5661-5669, IRL
Press Ltd, Oxford, GB; H. WEBER et al.:
"Formation of genes coding for hybrid pro-
teins by recombination between related,
cloned genes in *E. coli*"

CHEMICAL ABSTRACTS, vol. 104, no. 1, 6th
January 1986, page 156, no. 1676c, Colum-
bus, Ohio, US; A. FILLOUX et al.: "Cloning
and expression of a *Bacillus licheniformis*
alpha-amylase gene in *Pseudomonas*
aeruginosa"

CHEMICAL ABSTRACTS, vol. 103, no. 13, 30th
September 1985, page 142, no. 99556r, Co-
lumbus, Ohio, US; R. NAKAJIMA et al.:
"Nucleotide sequence of the *Bacillus*
stearothermophilus *alpha*-amylase gene"

JOURNAL OF BACTERIOLOGY, vol. 159, no. 3,
September 1984, pages 811-819, American
Society for Microbiology, Washington, D.C.,
US; N. VASANTHA et al.: "Genes for alkaline
protease and neutral protease from *Bacillus*
amyloliquefaciens contain a large open
reading frame between the regions coding
for signal sequence and mature protein"

JOURNAL OF BACTERIOLOGY, vol. 166, no. 2,
May 1986, pages 635-643, American Society
for Microbiology, Washington, D.C., US; G.L.
GRAY et al.: "Structural genes encoding the
thermophilic *alpha*-amylases of *Bacillus*
stearothermophilus and *Bacillus lichenifor-*
mis"

Description

The present invention is directed to hybrid polypeptides and processes for making the same. More particularly, the invention provides processes for producing hybrid DNA sequences which can express hybrid polypeptides having novel polypeptide sequences and novel physical properties.

Advances in the field of recombinant DNA technology have resulted in the cloning of various naturally occurring DNA sequences and the expression of the underlying recombinant DNA to produce biologically active recombinant polypeptides. For example, human growth hormone has been produced in *E. coli* by fusing the coding sequences for this protein to an *E. coli* promoter (1). In a second example, tissue plasminogen activator, another rare human protein, has also been produced in *E. coli* (2).

Modifications of certain recombinant polypeptides have been made to investigate the properties of such modified polypeptides. To this end, naturally occurring DNA sequences have been cloned and modified by deleting or replacing amino acid residues of the naturally occurring polypeptide to modify the physical properties of the recombinant polypeptide, as for example, by site directed mutagenesis as disclosed in U.S. Patent No. 4,518,584.

Recombinant polypeptides have also been modified by fusing recombinant DNA sequences. For example, the signal sequence from a plasmid-derived beta-lactamase was positioned at the amino-terminus of proinsulin through a common restriction site to facilitate the secretion of proinsulin (3).

Two different human alpha interferon DNA sequences have been combined by way of a common restriction site to form a DNA sequence containing sequences from alpha-1 interferon and alpha-2 interferon as described by Weissman (4). The alpha interferons expressed by such fused alpha interferon DNA sequence, however, demonstrated limited biological activity.

A major limitation in producing modified polypeptides by combining the underlying DNA at a restriction site, at more than one restriction site by way of a bridging synthetic oligonucleotide or by combining synthetic oligonucleotides to form the entire modified DNA sequence lies in the enormous amount of work which is required to produce a particular modified recombinant polypeptide. For example, such modifications require knowledge of the DNA and/or polypeptide sequence which if not available must be determined. Moreover, even if such sequences are known, the task of producing a modified polypeptide is far from simple and may result in a biologically inactive molecule.

Weber, et al., (5) disclose a method for making modified genes by *in vivo* recombination between DNA sequences encoding an alpha-1 and an alpha-2 human interferon sequence. A linear DNA sequence containing a plasmid vector flanked by the alpha-2 interferon gene on the 5' end and a portion of alpha-1 interferon gene on the 3' end was used to transfect a rec A positive strain of *E. coli*. Circularization of the linear plasmid by *in vivo* recombination between the partially homologous interferon gene sequences produced a number of modified interferon genes containing various portions of the alpha-1 and alpha-2 interferon gene sequences. Weber reports that some of these modified alpha interferon genes expressed modified alpha interferons having biological activity similar to unmodified alpha-2 interferons. Tommassen, et al., (1985) *The EMBO Journal* 4:1583-1587, also disclose a method of making modified genes by *in vivo* recombination between DNA sequences on a linear plasmid.

The efficiency of producing modified genes and polypeptides by *in vivo* circularization (recombination) of linear plasmids, as disclosed by Weber (5), is limited by the relative inefficiency of linear plasmids to transfect microorganisms as compared to circular plasmids. In addition, the two different but related genes on such linear plasmids are always separated by a replicable plasmid sequence. Circularization requires that the ends of the vector containing the two genes overlap to bring the two genes into close proximity with each other. The efficiency of recombination may therefore be limited by the linearity of such plasmid constructions.

Schneider, et al., (1981) *PNAS* 7:2169-2173 disclose the production of hybrid tryptophan synthetase α subunits formed by intragenic recombination by two different genes on two distinct and separate plasmids.

We have now developed circular vectors containing replicable DNA sequences and DNA sequences encoding at least two different parental polypeptides and recombined circular vectors containing the replicable DNA sequences and a hybrid DNA sequence encoding a hybrid polypeptide corresponding to part of each parental polypeptide.

We have now developed efficient processes for making such recombined circular vectors and hybrid polypeptides, as well as additional processes for isolating such recombined circular vectors.

We have furthermore developed biologically active hybrid polypeptides containing segments of polypeptide sequences derived from at least two parental polypeptides, as well as biologically active hybrid enzymes such as hybrid amylases and hybrid proteases.

Novel circular vectors containing a replicable DNA sequence and parental DNA sequences encoding all or part of at least two distinct parental polypeptides are disclosed. Such vectors are used in novel processes to produce recombined circular vectors containing said replicable DNA sequences and hybrid DNA sequences comprising: (1) a first DNA sequence encoding the amino-terminal portion of a hybrid 5 polypeptide corresponding to a first part of a first parental polypeptide sequence and (2) a second DNA sequence encoding a carboxy-terminal portion of said hybrid polypeptide corresponding to a first part of a second parental polypeptide sequence.

First and second parental DNA sequences encoding all or part of a first and second parental polypeptide sequence are ligated with a replicable DNA sequence to form a circular vector wherein said 10 parental DNA sequences are in proximity with each other. Rec positive microorganisms are transformed with the thus formed circular vector to form a cell population containing a multiplicity of said circular vector wherein crossover recombination of at least one of said circular vectors is mediated by the naturally occurring recombination mechanism of the rec positive microorganism. Such crossover recombination of the vector excises a third DNA sequence which encodes a second part of each of said first and second 15 parental polypeptide sequences to form a recombined circular vector comprising said replicable DNA sequences and said hybrid DNA sequences which encode a first part of each of said first and second parental polypeptide sequences. Such recombined vectors may be capable of expressing novel hybrid polypeptides or may be further modified to allow such expression.

A variation of the above described process utilizes a unique restriction site which is contained within 20 said third DNA sequence. Excision of the third DNA sequence produces a recombined circular vector which no longer contains the unique restriction site. Treatment of isolated circular vector and recombined circular vector with an endonuclease specific for said unique restriction site produces linearized vector and circular recombinant vector. The circular recombinant vector is isolated from linearized vector by exposing a microorganism to such vectors to transform the microorganism with the recombinant circular vector.

25 A process is also disclosed wherein said third DNA sequence comprises a DNA sequence which prevents expression of the second DNA sequence. Such sequences are typically transcription termination sequences. A functional promoter sequence is operably linked to said first DNA sequence. When the third DNA sequence is excised by a rec positive microorganism hybrid polypeptide is expressed. Such expression can be used to identify transformants which contain recombinant vector.

30 This latter process can be further modified by positioning a fourth DNA sequence three prime to said second DNA sequence. This fourth DNA sequence encodes a defined selection characteristic, such as tetracycline resistance, which may be used to isolate transformants containing recombinant vector which express the defined selection characteristics as a result of the excision of said third DNA sequence.

35 Brief Description of the Drawings

Figure 1 depicts a partial restriction map of the alpha amylase DNA sequences derived from B. licheniformis and B. stearothermophilus.

40 Figure 2A, 2B and 2C depict the nucleotide sequence for the alpha amylases derived from B. stearothermophilus and B. licheniformis and the consensus sequence between each.

Figure 3a depicts the construction of a plasmid containing DNA sequences encoding the alpha amylase of B. stearothermophilus.

Figure 3b depicts the construction of a plasmid containing a tandem arrangement of DNA sequences encoding a portion of B. stearothermophilus alpha amylase and a portion of B. licheniformis alpha amylase.

45 Figure 4 depicts the construction of a plasmid containing DNA sequences encoding alkaline proteases from B. subtilis and B. amyloliquefaciens which are separated by a synthetic oligonucleotide containing three unique restriction sites.

Figure 5 depicts the thermal stability of various hybrid alpha amylases at 90 °C as a function of time.

50 Figure 6A and 6B depict the amino acid sequence for the alpha amylases derived from B. stearothermophilus and B. licheniformis and the consensus amino acid sequence between each.

Figure 7 depicts the specific activity of various hybrid alpha amylases at various temperatures.

Figure 8 depicts the construction of a plasmid containing DNA sequences encoding alpha amylases from B. stearothermophilus and B. licheniformis wherein the alpha amylase DNA sequences are separated by a synthetic transcription termination sequence and a DNA sequence encoding tetracycline resistance is positioned 3' to the sequences encoding the alpha amylase from B. stearothermophilus.

Detailed Description

The inventor has demonstrated that novel hybrid polypeptides having unique biological activity can be produced by homologous crossover recombination of DNA sequences contained on a circular vector.

5 Parental DNA sequences encoding all or part of at least two different polypeptides were ligated with a replicable DNA sequence to form a circular vector. The parental DNA sequences may be joined in tandem relationship whereby said sequences are in very close proximity or may be inserted at various positions within the circular vector to vary their proximity. Such variation in proximity may be useful in controlling the efficiency of recombination or may impose physical restraints which limit the regions in such parental DNA
10 sequences wherein recombination may occur. Rec positive microorganisms transformed with the thus ligated circular vector were believed to initiate crossover recombination in regions of sequence homology between the parental DNA sequences. Recombined circular vectors were formed containing hybrid DNA sequences containing various portions of each parental DNA sequence. The point of actual crossover did not necessarily correspond to those regions of the parental DNA sequences which were homologous, such
15 homology only being necessary to initiate crossover recombination. These hybrid DNA sequences encoded biologically active polypeptides which contained various amino-terminal and carboxy-terminal portions derived from each of the parental polypeptides.

As used herein, a "hybrid polypeptide" refers to recombinant polypeptides having an amino acid sequence which is a combination of partial sequences derived from at least two parental amino acid sequences. In some of the various preferred embodiments disclosed, hybrid polypeptides contained a variable amount of the amino-terminal peptide sequence derived from a specific B. stearothermophilus alpha amylase and a carboxy-terminal peptide sequence derived from a specific B. licheniformis alpha amylase. Other embodiments disclose hybrid polypeptides containing variable amounts of amino-terminal sequences derived from a specific B. subtilis alkaline protease and carboxy-terminal amino acid sequences 25 from a specific B. amyloliquefaciens alkaline protease.

These specific embodiments are presented by way of example and are not intended to limit the scope of the present invention. In particular, alpha amylases or alkaline proteases from sources other than those specifically disclosed may be employed in practicing the present invention. Such parental polypeptides include for example alpha amylases derived from B. coagulans (e.g., ATCC 7050), B. amyloliquefaciens -
30 (e.g., ATCC 23842), B. megaterium (e.g., ATCC 6458), B. alcalophilus (e.g., ATCC 21591), and B. cereus - (e.g. ATCC 21768). Examples of other alkaline proteases include those derived from B. licheniformis (e.g. ATCC 21415), B. alcalophilus (e.g., ATCC 21522) and B. cereus (e.g. ATCC 21768).

In general, the present invention may also be used to generate hybrid polypeptides by combining amino acid sequences from related or unrelated polypeptides. Hybrid polypeptides containing related amino acid sequences may exhibit unique physical properties whereas hybrids of unrelated polypeptides may produce a bifunctional hybrid polypeptide. The only limitation in choosing parental polypeptides is functional. The underlying DNA sequences encoding each of the parental polypeptides must have sufficient sequence homology to permit in vivo recombination.

Examples of various parental polypeptides which may be combined according to the present invention 40 include plasminogen activators, growth hormones, interferons, lymphotoxins, aspartyl proteases, B. thuringiensis toxins, celluloses, and glucoamylases.

A "hybrid DNA sequence" is a DNA sequence encoding the above described hybrid polypeptides. In some disclosed embodiments such hybrid DNA sequences further include a functional promoter operably linked to said hybrid DNA sequence whereby the hybrid polypeptide encoded by the underlying hybrid
45 DNA can be expressed. Such promoters may be the native promoter of a parent DNA sequence or may be derived from sources known to those skilled in the art and functionally inserted by well known methods to effect expression of hybrid polypeptide. In some embodiments a promoter sequence is not required to produce a hybrid DNA sequence. A promoter sequence may be introduced into such recombined vectors after recombination to enable expression of the hybrid DNA sequence.

50 A "parental DNA sequence" refers to a DNA sequence encoding all or part of a particular polypeptide sequence. As disclosed herein, a first part from at least two parental DNA sequences are recombined in vivo to form a hybrid DNA sequence encoding a hybrid polypeptide. Depending on the particular embodiment, a second part of each parental DNA sequence is excised during formation of said hybrid DNA sequence.

55 A "rec positive microorganism" refers to genotypes of prokaryotic and eukaryotic microorganisms which are capable of recombination and in particular are capable of mediating recombination of the circular vector of the present invention. Such microorganisms in general include prokaryotes such as Bacillus, E. coli and other species of the Enterobacteriaceae bacteria, Pseudomonas, Corynebacteria, Lactobacilli,

Streptomyces, and Agrobacterium, and eukaryotes such as Saccharomyces cerevisiae and other yeasts, Aspergillus and other filamentous fungi, and tissue culture cells from avian or mammalian origins.

The "replicable DNA sequences" which form a part of the circular vector and recombined vector of the present invention contain replication and control sequences which are derived from vector species which are compatible with the particular rec positive microorganism used to mediate in vivo recombination. Such replicable DNA sequences ordinarily carry a replication site as well as sequences which encode proteins that are capable of providing phenotypic selection in transformed cells. For example, when a rec positive E. coli is chosen for in vivo recombination, DNA sequences derived from pBS42(17) (ATCC #37279), pBR322-(25) (ATCC #37017), pUC series plasmid (26), and RSF1010(44) may be used. When a rec positive eukaryote such as Saccharomyces, Aspergillus, or mammalian tissue culture cells is used replicable DNA sequences may be derived respectively from the yeast 2- μ vector (35), the Aspergillus integration vector p3SR2(36) and SV40(37).

As used herein, a functional promoter operably linked to a coding DNA sequence refers to a promoter sequence which controls the transcription and translation of the coding sequence. The promoter sequence is chosen so that it is functional in the microorganism chosen for expression. For example promoter sequences (including ribosome binding sites) derived from Lambda P_L(38), as well as the trp(39) or tac(40) promoters may be operably linked to coding sequences to express polypeptide in E. coli. When B. subtilis is the expression host the B. subtilis alkaline protease promoter (32) or alpha amylase promoter of B. amyloliquefaciens (41) may be used. Expression in yeast may be under the control of the promoter for the GAPDM of S. cerevisiae(42) while expression in filamentous fungi may be mediated by the promoter for B-glucosidase from Aspergillus niger(43). The early promoter of SV40(37) is preferred for expression in mammalian cells.

General Methods

"Digestion" of DNA refers to catalytic cleavage of the DNA with an enzyme that acts only at certain locations in the DNA. Such enzymes are called restriction enzymes, and the sites for which each is specific is called a restriction site. "Partial" digestion refers to incomplete digestion by a restriction enzyme, i.e., conditions are chosen that result in cleavage of some but not all of the sites for a given restriction endonuclease in a DNA substrate. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements as established by the enzyme suppliers were used. In general, about 1 microgram of plasmid or DNA fragment is used with about 1 unit of enzyme and about 20 microliters of buffer solution. Appropriate buffers and substrate amounts with particular restriction enzymes are specified by the manufacturer. Incubation times of about one hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After incubation, protein is removed by extraction with phenol and chloroform, and the digested nucleic acid is recovered from the aqueous fraction by precipitation with ethanol. Digestion with a restriction enzyme may be followed by bacterial alkaline phosphatase hydrolysis of the terminal 5' phosphates to prevent the two restriction cleaved ends of a DNA fragment from forming a closed loop that would impede insertion of another DNA fragment at the restriction site.

"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest by a polyacrylamide gel electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the DNA from the gel generally by electroelution (6,7).

"Ligation" refers to the process of forming phosphodiester bonds between two double-stranded nucleic acid fragments (8). Unless otherwise stated, ligation was accomplished using known buffers in conditions with ten units of T4 DNA ligase ("ligase") per 0.5 microgram of approximately equal molar amounts of the DNA fragments to be ligated.

"Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or chromosomal integrant. Unless otherwise stated, the method used herein for transformation of E. coli is the CaCl₂ method of Mandel (9) and for Bacillus, the method of Anagnostopolous (10).

"Oligonucleotides" are short length single or double stranded polydeoxynucleotides which were chemically synthesized by the method of Crea et al., (11) and then purified on poly-acrylamide gels.

"Preparation" of DNA from transformants means isolating plasmid DNA from microbial culture. Unless otherwise provided the alkaline/SDS method was used (12).

The following specific examples are intended to illustrate more fully the nature of the present invention without acting as a limitation upon its scope.

EXAMPLES OF PREFERRED EMBODIMENTS

In one example of a preferred embodiment, B. stearothermophilus alpha amylase DNA sequences containing the native promoter for B. stearothermophilus alpha amylase operably linked to the entire DNA sequence encoding B. stearothermophilus alpha amylase was cloned and isolated. The DNA sequence encoding the alpha amylase of B. licheniformis was similarly cloned.

A PstI restriction site near the 5' end of the structural DNA sequence encoding B. licheniformis alpha amylase and a PstI restriction site near the 3' end of the structural DNA sequence encoding B. stearothermophilus alpha amylase were used to ligate DNA sequences encoding each of the parental amyloses in a tandem arrangement on a circular vector.

Homologous crossover recombination between the alpha amylase DNA sequence was mediated by a rec positive microorganism to form hybrid DNA sequences encoding a number of hybrid amyloses derived from B. licheniformis and B. stearothermophilus. Transformants containing such hybrid DNA sequences were identified by detecting hybrid alpha amylase activity.

In an example of another embodiment, vector which had not undergone homologous crossover recombination was linearized by digestion with PstI. Vectors which had recombined to form hybrid DNA sequence encoding hybrid alpha amyloses no longer contained the PstI site used to join the two alpha amylase DNA sequences. Since such PstI site was unique in the vector constructed, recombined vector resisted linearization. Such non-linearized recombinant vector was isolated from linearized vector by transformation of a second microorganism.

In both embodiments crossover recombination initiated at homologous sequences of the B. stearothermophilus and B. licheniformis alpha amylase encoding DNA sequences formed mutant vectors containing hybrid DNA sequences encoding the promoter of B. stearothermophilus alpha amylase, various portions of the amino-terminal sequence of B. stearothermophilus alpha amylase and various portions of the carboxy-terminal sequence of B. licheniformis alpha amylase. The various hybrid alpha amyloses expressed by such hybrid DNA sequences demonstrated unique properties as compared to the parental alpha amyloses from B. stearothermophilus and B. licheniformis. Other examples of preferred embodiments are also disclosed.

EXAMPLE 1

A. Cloning of the alpha amylase genes of Bacillus licheniformis and Bacillus stearothermophilus.

B. licheniformis or B. stearothermophilus DNA was partially digested with Sau3A and DNA fragments larger than 6 kb (kilobases) were separated on sucrose gradients. The B. licheniformis strain used as a source of genomic DNA was strain MCIB 8061 obtained from the National Collection of Industrial Bacteria, Torrey Research Station, Aberdeen, Scotland. The B. stearothermophilus strain used as a source of genomic DNA was strain NZ-3 which has been deposited by Assignee in the American Type Culture Collection under accession number 39536. The bacteriophage lambda vector λ1059 (13) was completely digested with BamHI and treated with calf intestinal phosphatase to minimize self-ligation. 500 ng of vector and 500 ng of bacterial DNA fragments were ligated in a 20 ul reaction volume using T4 DNA ligase. The DNA contained in the reaction was packaged in vitro using a commercial (Promega Biotec) (Madison, WI) packaging extract (14) and then used to infect E. coli Q358 (15) (6) and Q359, (a P2 lysogen of Q358) (15). The number of recombinant plaques was approximately 2.5×10^3 in typical reactions.

Approximately 5×10^3 plaques were plated onto E. coli Q359 bacteria on LB plates containing 0.5% starch to screen for alpha amylase activity. These plates were exposed to iodine vapors to stain the starch (16). Five plaques which were surrounded by clear halos were found in the B. licheniformis library. Three such plaques were found in the B. stearothermophilus library. DNA was prepared from each one of the amylase positive B. licheniformis phage (designated λ-amy-BL) and the B. stearothermophilus phage (designated λ-amy-BS).

Referring now to Fig. 3B, the E. coli-B. subtilis shuttle vector pBS42 (17), ATCC 37279, was cleaved with BamHI or EcoRI and treated with calf intestinal alkaline phosphatase to minimize self ligation. This cleaved shuttle vector was ligated with DNA from λ-amy-BL which had also been digested with BamHI or EcoRI respectively. Transformation of E. coli 294, (18), ATCC No. 31446, gave rise to numerous chloramphenicol resistant transformants, many of which showed clear halos when stained with iodine vapors. Digestion of each one of the amylase positive (amy +) BamHI and EcoRI subclones revealed inserted fragments of 9.4 kb and 3.2 kb respectively. These results show that the alpha amylase gene of B. licheniformis was contained entirely within either of these fragments. The EcoRI subclone was designated pBS42-BL and is shown in Fig. 3B.

The plasmid pBS42-BL was subjected to further digestions with various restriction enzymes in order to generate the restriction map depicted in Fig. 1. Various subfragments of the inserted DNA were subcloned into M13 sequencing vectors (19) in order to determine preliminary DNA sequence information by the dideoxy chain termination method (21). Sequences near the unique KpnI site were found to be highly homologous to those of the alpha amylase gene of *B. amyloliquefaciens*. By making the assumption that the *B. licheniformis* amylase gene was structurally similar to the *B. amyloliquefaciens* gene (41) the appropriate fragments to sequence in detail were easily chosen. Figure 1 shows the regions that were completely sequenced. An open reading frame of 1536 bp was found which had a high degree of homology to the entire alpha amylase gene of *B. amyloliquefaciens*. The DNA sequence of *B. licheniformis* alpha amylase is shown in Fig. 2A and 2B.

DNA from λ -amy-BS was digested with various restriction enzymes, separated on a 1% agarose gel, transferred to a nitrocellulose filter (21), and subjected to DNA-DNA hybridization (22). The probe used was the PstI-SstI fragment containing most of the coding sequences of the *B. licheniformis* amylase gene (Fig. 1). This fragment was radioactively labeled with γ -³²P using the nick translation method (23). Hybridization was performed under standard high stringency conditions (24). A BamHI fragment of 1.8 kb and a Sal I fragment of 1.8 kb were among the positively hybridizing fragments. Both of these fragments were subcloned into pBR322, and cleaved with BamHI or Sal I and ligated with BamHI or Sal I digested pBR322 to generate plasmids pBR322BS-B and pBR322BS-S as depicted in Figure 3A. A detailed restriction map of the inserted fragments is shown in Fig. 1. This information was used to isolate a variety of subfragments for cloning into M13 sequencing vectors for preliminary DNA sequence analysis. Sequences near the unique KpnI site were found which were highly homologous to those of the alpha amylase genes of both *B. amyloliquefaciens* and *B. licheniformis*. Assuming that the structure of the *B. stearothermophilus* alpha amylase gene was similar to the other two it was possible to choose which other subfragments of the inserted fragments in pBR322BS-B and pBR322BS-S to sequence completely. The entire sequence of *B. stearothermophilus* alpha amylase is shown in Fig. 2A and 2B. These studies revealed a 1581 bp open reading frame which was highly homologous to that of the other alpha amylase genes.

B. Construction of *B. stearothermophilus* alpha amylase plasmid vector pUC13BS and *B. stearothermophilus*-*B. licheniformis* alpha amylase precursor plasmids pUC13BSBL and pBS42BSBL.

As depicted in Figure 3A, DNA from pBR322BS-B was digested with BamHI and a 1.8 kb fragment (fragment A) was isolated. Plasmid pBR322BS-S was doubly digested with BamHI and Sal I and a 1.8 kb fragment (fragment B) was isolated. Plasmid pBR322 was doubly digested with BamHI and Sal I and the larger vector fragment (fragment C) was isolated. Fragments A, B, and C were joined by ligation. The reaction was transformed into *E. coli* 294. One ampicillin resistant colony, containing plasmid pBR322BS was isolated. This plasmid was digested completely with HindIII and partially with Sal I and a 4.2 kb fragment (fragment D) was isolated. The vector pUC13 (26) was digested with HindIII and Sal I and the larger vector fragment (fragment E) was isolated. Fragments D and E were joined by ligation and transformed into *E. coli* 294. An ampicillin resistant colony containing plasmid pUC13BS was isolated. This colony was found to produce a zone of clearing on an LB starch agar plate, and therefore was presumed to contain on its plasmid the entire gene of *B. stearothermophilus* alpha amylase.

Referring now to Fig. 3B, the *B. licheniformis* alpha amylase plasmid pBS42BL was cleaved with SstI and PstI and the smaller fragment (fragment F) was isolated. The *B. stearothermophilus* plasmid pUC13BS was also cleaved with SstI and PstI and the larger vector fragment (fragment G) was isolated. Fragments F and G were joined by ligation and then used to transform *E. coli* 294. One ampicillin resistant colony containing plasmid pUC13BSBL was selected. This colony did not produce an active alpha amylase as determined by its failure to produce a halo of clearing on an LB starch agar plate. This result was expected because pUC13BSBL lacks the carboxy-terminal codons of the *B. stearothermophilus* alpha amylase gene and also the amino-terminal codons of the *B. licheniformis* alpha amylase gene. In addition the codons of the latter gene are not in the same reading frame as those of the former gene. The plasmid pUC13BSBL was cleaved completely with BamHI and partially digested with EcoRI. Fragment H was isolated. The *E. coli*-*B. subtilis* shuttle vector pBS42 was digested with BamHI and EcoRI and the larger vector fragment (fragment I) was isolated. Fragments H and I were joined by ligation and transformed into *E. coli* 294. One chloramphenicol resistant transformant, pBS42BSBL was saved. This colony produced no alpha amylase as determined by its failure to produce a halo of starch clearing on LB starch agar plates. This was expected because this plasmid contains the same alpha amylase sequences as pUC13BSBL.

C. The generation of hybrid alpha amylase DNA sequences and expression of their encoded hybrid proteins.

Ten ng of plasmid pBS42BSBL was used to transform E. coli 294 (rec A positive). The reaction was plated on LB-starch plates supplemented with 12.5 ug/ml chloramphenicol. About 3×10^4 colonies were obtained. Six of these produced halos due to starch hydrolysis. These colonies were presumed to contain plasmids in which the B. stearothermophilus and B. licheniformis alpha amylase DNA sequence within the plasmid had recombined by homologous recombination to give rise to hybrid DNA sequences encoding active hybrid alpha amylases. The region of homology (in which recombination was expected to occur) between the two alpha amylase gene fragments in pBS42BSBL is about 1.0 kb. These data would therefore indicate that the frequency for such recombination events was $6/3 \times 10^4$ or 2×10^{-4} .

EXAMPLE 2

In order to reduce the background of colonies containing pBS42BSBL a plasmid preparation from pBS42BSBL transformed E. coli 294 was digested with PstI prior to a second transformation. It was reasoned that in all cases in which recombination between the B. stearothermophilus and B. licheniformis gene fragments had occurred the PstI site (unique in the plasmid) would have been deleted. Thus such hybrid recombinant plasmids would be resistant to PstI digestion, whereas unrecombinant plasmids would be linearized by PstI digestion. The transformation efficiency of circular plasmids is two to three orders of magnitude greater than that for such linearized forms. It was therefore expected that the digestion of the pBS42BSBL with PstI prior to transformation would increase the ratio of colonies containing the recombinant plasmids to those containing unrecombinant plasmids. Thus 1000 ng of a PstI-treated plasmid preparation from pBS42BSBL transformed E. coli 294 was used to transform E. coli 294 a second time. 2032 colonies were obtained. 517 (approximately 25%) produced halos of starch hydrolysis on LB starch agar plates indicating the synthesis of active hybrid alpha amylase.

EXAMPLE 3

A. Characterization of the hybrid DNA sequences contained in alpha amylase producing pBS42BSBL transformants of E. coli 294.

The assumption was made that the amy+ colonies arose as a result of single crossover events within the pBS42BSBL plasmid between the B. stearothermophilus and B. licheniformis gene fragments in a region in which they have sequence homology. It was reasoned that such recombinant genes would contain 5' sequences contributed by the B. stearothermophilus gene and 3' sequences contributed by the B. licheniformis gene. In order to verify this notion the following experiment was performed. Low homology regions of 16-18 nucleotides at intervals of about 150 bp were selected. Oligonucleotides, indicated as probes 1-9 in Figure 2A and 2B, corresponding to the sense strand of the B. stearothermophilus gene in these regions were synthesized (11). These oligonucleotides were end-labeled with $\gamma^{32}\text{P}$ -ATP and T4 polynucleotide kinase in order to produce hybridization probes to detect B. stearothermophilus sequences. It was reasoned that all sequences 5' of the crossover locus would be derived from the B. stearothermophilus gene and would therefore hybridize to the corresponding (perfect homology) oligonucleotide probes. Sequences 3' of the crossover locus would be derived from the B. licheniformis gene and would therefore fail to hybridize to the corresponding (low homology) oligonucleotide probes under the conditions employed. Twelve amy+ colonies postulated to contain recombinant hybrid alpha amylase DNA sequences as well as colonies containing pUC13BS, pBS42BL, and pBS42BSBL were selected for DNA-DNA hybridization with each of the oligonucleotide probes. All of these colonies were inoculated onto each of 9 nitrocellulose filter paper strips. These strips were placed on an LB agar plate. The plate was incubated overnight at 37°C to allow colony growth. The filters were then prepared for hybridization by standard methods (27). In separate vessels the nine strips were incubated with each of the oligonucleotide probes using standard methods for low stringency hybridization. (2) The filters were washed in 2xSSC and 0.1% SDS at 37°C, then air dried and autoradiographed. The results are shown in Table 1.

5
10
15
20
25
30
35
40
45
50
55

TABLE 1
Signals with Oligonucleotide Probes

<u>Hybrid</u>	Crossover loci position in B. stearothermo- philus alpha amylase gene									
	1	2	3	4	5	6	7	8	9	10
1	-	-	-	-	-	-	-	-	32 to 154	
2	-	-	-	-	-	-	-	-	32 to 154	
3	-	-	-	-	-	-	-	-	32 to 154	
4	-	-	-	-	-	-	-	-	32 to 154	
5	-	-	-	-	-	-	-	-	612 to 746	
6	-	-	-	-	-	-	-	-	318 to 450	
7	-	-	-	-	-	-	-	-	318 to 450	
8	-	-	-	-	-	-	-	-	318 to 450	
9	-	-	-	-	-	-	-	-	467 to 595	
D	-	-	-	-	-	-	-	-	767 to 912	
E	-	-	-	-	-	-	-	-	767 to 912	
11	-	-	-	-	-	-	-	-	612 to 746	
F	-	-	-	-	-	-	-	-	1067 to 1197	
G	-	-	-	-	-	-	-	-	1067 to 1197	
PBS42BL	-	-	-	-	-	-	-	-	-	
PUC13BS	+	+	+	+	+	+	+	+	+	
PBS42BSBL	+	+	+	+	+	+	+	+	+	

Numbers are nucleotide positions of *B. stearothermophilus* DNA sequence given in Figure 2A and 2B. It was assumed that all positive signals were due to the presence of the entire sequence complementary to the hybridizing probes.

As expected the probes all hybridized to *B. stearothermophilus* sequences but not to *B. licheniformis* sequences. This is indicated by positive signals of hybridization with all probes to the DNA from cells containing pUC13BS which contains the entire *B. stearothermophilus* alpha amylase gene and negative hybridization signals to the DNA of cells containing PBS42BL which contains the entire *B. licheniformis* alpha amylase gene but no sequences from the *B. stearothermophilus* gene. The DNA from cells containing PBS42BSBL gave positive signals with all probes except probe 9 because probe 9 corresponds to a region of the *B. stearothermophilus* gene 3' of that present in this plasmid.

The 14 putative hybrids showed a variety of hybridization patterns. For example hybrids 1, 2, 3, and 4 hybridized to probe 1 but not to the other (more 3') probes 2-8. This indicated crossover between sequences corresponding to probes 1 and 2. In another example, hybrid 9 hybridized to probes 1-4 but not to the more 3' probes 5-9. This indicated a crossover between the sequences corresponding to probes 4 and 5. As shown in Table 1 other crossover regions were similarly identified in the remaining hybrids. In other experiments (not shown) hybrids with crossovers between any pair of probe regions were found although with highly variable frequencies, e.g. crossovers between probes 1 and 2 were very common (about 20%) whereas crossovers between probe regions 2 and 3 were quite rare (about 1%).

The above results indicate that the crossovers between the alpha amylase gene fragments were widely dispersed over the approximately 1.0 kb region of homology between the two genes. However, it was of interest to study this distribution in more detail. Thus we determined the DNA sequence of the hybrid genes

in their crossover regions by direct sequencing of sodium hydroxide collapsed plasmids using the dideoxy chain termination method (28). For a given hybrid, synthesis was primed using the most 3' synthetic oligonucleotide which hybridized to the hybrid. In all cases the sequences determined clearly showed the crossover loci. The crossover loci for the twelve hybrids are shown in the stippled boxes of Fig. 2A and 2B.

5 For example, in hybrid 9 (Fig. 2A) the crossover occurred between bp 585 and bp 600, as indicated by the presence of sequences derived from the *B. stearothermophilus* gene 5' of this region and the sequences derived from the *B. licheniformis* gene 3' of this region.

10 B. Analysis of the hybrid alpha amylase enzymes produced by plasmid hybrids 4, 6, and D.

E. coli 294 cells containing pBS42BL or plasmid hybrids 4, 6 or D were cultured overnight in shaker flasks (120 rpm) containing LB medium supplemented with 12.5 ug/ml chloramphenicol. E. coli 294 cells containing plasmid pUC13BS were similarly cultured except that 50 ug/ml of carbenicillin rather than chloramphenicol was added to the LB medium. Cells were collected by centrifugation and fractionated into cytoplasmic and periplasmic fractions by the osmotic shock method (29). These fractions were assayed for alpha amylase activity by the micro-Phaedabas assay (Pharmacia, Inc., Piscataway, NJ) which measures starch hydrolysis. In all cases most of the activity (80-85%) was found to be associated with the periplasmic fraction. Thus this fraction was used for purification of the alpha amylases produced in the five cultures.

To purify the enzymes, the periplasmic fractions were poured over a column containing insoluble starch at 4°C which resulted in the binding of the alpha amylases to the starch. The enzymes were then eluted from the column by raising the temperature to 50°C. Starch was removed from the enzymes by gel permeation chromatography on a P-2 column (Bio-Rad Laboratories, Richmond, CA) followed by DEAE chromatography (30). Each of the purified alpha amylases was pure as judged by its homogeneity on SDS-polyacrylamide gels. The protein concentration for each purified protein was determined by the dye binding method of Bradford (31).

The thermostabilities of the purified alpha amylases were determined as follows. Equal concentrations of the enzyme were incubated at 90°C. Aliquots were removed at various times and assayed for alpha amylase activity at 70°C using the micro-Phaedabas assay. The results are shown in Fig. 5. The parental *B. licheniformis* enzyme produced from the pBS42BL plasmid retains essentially all of its activity even after prolonged incubation (120 min.) at 90°C, whereas the parental *B. stearothermophilus* enzyme produced from the plasmid pUC13BS loses about 50% of its activity under these conditions. The hybrid enzymes encoded by the hybrid DNA sequences of hybrids 4, 6, and D show a variety of thermostabilities. Hybrid 4 retains essentially all of its activity after incubation at 90°C for 120 min. As shown in Fig. 6 this protein is structurally identical to the *B. licheniformis* enzyme except at its amino-terminus where the first fifteen amino acids are encoded by the *B. stearothermophilus* gene. This strong similarity between the hybrid 4 protein and the *B. stearothermophilus* protein may account for their similar resistance to heat inactivation. In contrast, hybrid D protein retains only 10% of its activity after incubation for 120 min. at 90°C. This polypeptide is highly chimeric in that approximately its entire amino terminal half is encoded by the *B. stearothermophilus* gene whereas the carboxyl-terminal half is encoded by DNA from the *B. licheniformis* gene (see Fig. 6). Since the thermostability of the hybrid 4 protein is less than that of either parent it may be that an interaction(s) between the amino-terminal and carboxy-terminal halves of alpha amylases are required for thermal stability and that these interactions are altered in the hybrid protein. The protein from hybrid 6 retains about 50% of its activity after incubation at 90°C for 120 min., and therefore has the same thermostability as the parental *B. stearothermophilus* enzyme. The hybrid 6 protein is composed primarily of residues encoded by the *B. licheniformis* gene but the amino-terminal 73 residues are those of the *B. stearothermophilus* protein (see Fig. 6). This heterologous amino-terminus may have a slightly destabilizing effect on the protein structure thus possibly contributing to its reduced stability in comparison to the parental *B. licheniformis* enzyme. These results show that hybrid alpha amylases can be expected to show a range of thermostabilities which may be the same or different from those of the parental enzymes.

50 The specific activities of the parental and hybrid alpha amylases purified as described above were also determined at four different temperatures. These data are shown in Fig. 7. The parental *B. stearothermophilus* enzyme has the highest specific activity at all temperatures, whereas the parental *B. licheniformis* enzyme is much less active at all temperatures. The hybrids 4 and 6 which as described above, contain only short stretches of amino-terminal residues derived from the *B. stearothermophilus* gene more closely 55 resemble the *B. licheniformis* enzyme in their specific activity profiles. Hybrid D alpha amylase, however, has specific activities intermediate between those of the parental enzymes. The apparent large reduction of activity of this enzyme at 90°C compared to 70°C may be largely due to its marked instability at 90°C as noted above. These data indicate that hybrid alpha amylases show a variety of specific activities.

EXAMPLE 4

In another preferred embodiment, hybrid alkaline proteases derived from B. subtilis and B. amyloliquefaciens were produced. A synthetic oligonucleotide sequence containing more than one unique restriction site was used to link DNA sequences encoding the B. subtilis and B. amyloliquefaciens alkaline proteases. Treatment of vector with endonucleases specific for each unique restriction site after recombination in a rec positive microorganism reduced background transformation by non-recombined vector.

A. Construction of the B. subtilis-B. amyloliquefaciens alkaline protease hybrid precursor plasmid pBS42BSBA.

As depicted in Figure 4 the plasmid pS168.1 (44,32) containing the B. subtilis alkaline protease gene was digested with EcoRI and Ncol. The smaller fragment (fragment A) was isolated. The plasmid pS4-5 (44,33) containing the entire B. amyloliquefaciens alkaline protease gene was digested with EcoRI and Aval. The larger vector fragment (fragment B) was isolated. Two complimentary synthetic oligonucleotides containing Ncol and Aval cohesive termini and PstI, Sal I, and KpnI sites between these termini were annealed to form fragment C by heating at 95 °C and cooling to 23 °C. Fragments A, B, and C were joined by ligation. The thus ligated vector was used to transform E. coli 294. A chloramphenicol resistant colony containing the plasmid pBS42BSBA was saved. B. subtilis strain BG2036 (44) contains deletions of the chromosomal alkaline protease and neutral protease genes. Strain BG2036 produced no protease when transformed with pBS42BSBA as determined by its failure to produce a halo of clearing on LB plates containing 0.1% skim milk. This result was expected because the plasmid lacks the carboxy-terminal codons of the B. subtilis alkaline protease gene and the amino-terminal codons of the B. amyloliquefaciens alkaline protease gene. In addition the codons of the latter gene are not in the same reading frame as those of the former gene. In contrast B. subtilis strain BG2036, containing either plasmid pS168.1 or pS4-5, produced active alkaline protease as determined by the production of halos of clearing on LB-skim milk agar plates. This result was expected because these latter two plasmids contain complete alkaline protease genes. It should be noted here that E. coli 294 transformed with pS168.1, pS4-5 or pBS42BSBA produced no alkaline protease as determined by a lack of halo production on LB skim milk agar plates. This may indicate that Bacillus alkaline protease promoters are not active in E. coli although other explanations are possible.

B. Generation of hybrid alkaline protease DNA sequences and expression of hybrid proteins.

One ng of plasmid pBS42BSBA was used to transform E. coli 294. The reaction was plated on LB chloramphenicol agar plates. About 2x10³ colonies were obtained. Unlike the case for alpha amylases, alkaline proteases are not expressed in E. coli, even from complete genes. In order to determine whether recombination had occurred between the homologous regions comprising about 1 kb of the alkaline protease gene fragments of B. subtilis and B. amyloliquefaciens present on the plasmid it was necessary to use a hybridization technique. In the hybridization experiment we tested for the presence of fragment C in the plasmids contained in the transformants. We reasoned that if recombination between the DNA sequences had occurred then in all cases the sequences comprising fragment C would be deleted, whereas unrecombined plasmids would still contain these sequences. The hybridization experiment was performed as follows. The colonies were lifted from the plates on nitrocellulose filters. The filters were then prepared for hybridization by standard methods (27). Hybridization was carried out at low stringency by standard methods. The probe used was the sense (upper) strand of fragment C end-labelled with $\gamma^{32}\text{P}$ -ATP and T4 polynucleotide kinase (34). By this method about 1.0x10³ colonies were tested. Three were found which did not hybridize to the probe and were therefore presumed to contain plasmids in which recombination between the two partially homologous alkaline protease gene fragments had occurred.

EXAMPLE 5

In another experiment enrichment of such putative recombinants was achieved by predigestion of a plasmid preparation derived from BS42BSBA transformed E. coli 294. The plasmid preparation was digested with a combination of the restriction enzymes PstI, Sall, and KpnI prior to transformation of E. coli 294. 3 ng of plasmid thus digested gave rise to eight chloramphenicol resistant transformants. These colonies were tested by the hybridization procedure described above for the presence of the nucleotide sequence contained in fragment C. Seven of these colonies failed to hybridize and were therefore

presumed to contain plasmids in which recombination between the two partially homologous gene sequences had occurred. In order to test whether the negatively hybridizing colonies contained plasmids which contained hybrid genes encoding active hybrid alkaline proteases, these plasmids were isolated and transformed into B. subtilis BG2036. This strain produced a zone of clearing on LB skim milk chloramphenicol agar plates upon transformation with any of the plasmids postulated to contain recombinant alkaline protease hybrid genes. In contrast the putative unrecombined pBS42BSBA plasmids (8 isolates tested) failed to confer upon strain BG2036 transformants the ability to produce active alkaline protease as indicated by their failure to produce clearing zones on skim milk plates.

10 EXAMPLE 6

A. Characterization of hybrid DNA sequences contained in alkaline protease producing pBS42BSBA transformants of E. coli 294.

15 The assumption was made that the alkaline protease positive colonies arose as a result of single crossover events within the pBS42BSBA plasmid between the B. subtilis and B. amyloliquefaciens DNA sequences which were initiated in a region in which they have sequence homology. It was reasoned that such recombinant genes would contain 5' sequences contributed by the B. subtilis gene and 3' sequences contributed by the B. amyloliquefaciens gene. Early crossovers would be expected to contain larger 3' 20 sequences contributed by the B. amyloliquefaciens genes whereas small segments of 3' sequences of the B. amyloliquefaciens gene would be present in later crossovers. There is a unique Pvull site present in pBS42BSBA which occurs within the B. amyloliquefaciens alkaline protease coding sequence (see Fig. 4). Crossovers in which the 3' region contributed by the B. amyloliquefaciens gene extended 5' of the Pvull site would result in plasmids with a unique Pvull site. Furthermore, this Pvull site would be located closer to the 25 unique EcoRI site (located 5' of the promoter) than in pBS42BSBA plasmids which had not recombined. Putative hybrids 2, 6, 7, and 8 digested with EcoRI and Pvull showed a restriction pattern that indicated that the Pvull site was present. In contrast, crossovers in which the 3' region contributed by the B. amyloliquefaciens gene did not extend 5' to the Pvull site would result in plasmids without Pvull sites. Putative hybrids 1, 3, and 4 belong to this latter category as evidenced by their resistance to digestion with 30 Pvull. These data indicate that early and late crossovers were present in the plasmids containing the putative hybrid alkaline protease genes.

B. Analysis of hybrid alkaline proteases encoded by hybrid alkaline protease DNA sequences.

35 For preliminary characterization of the hybrid proteins produced by B. subtilis BG2036 containing plasmids encoding the hybrid alkaline protease genes described above, the Km's were determined using a synthetic substrate. Crude culture supernatants were used as the source of enzyme. The substrate used was succinyl-L-alanine-L-alanine-L-proline-L-tyrosine-L-para-nitroanalide. The release of the product paranitroanalide was monitored colometrically by measurement of absorbance at 430nm using a Hewlett-Packard Diode Array 40 Spectrophotometer Model 8451A. The Km's of the parental B. subtilis and B. amyloliquefaciens enzymes were also determined. The results of this study are shown in Table 2.

45

50

55

TABLE 2

Km's of parental and hybrid alkaline proteases on the synthetic substrate succinyl-L-ala-L-ala-L-pro-L-tyr-L-para-nitroanalide ¹	
Plasmid	Km (Mx10 ⁵)
pS4-5	2.38 ($\pm .09$)
pS168.1	3.39 ($\pm .15$)
hybrid 1	5.54 ($\pm .10$)
hybrid 2	5.12 ($\pm .10$)
hybrid 3	5.42 ($\pm .06$)
hybrid 4	5.39 ($\pm .11$)
hybrid 6	2.86 ($\pm .13$)
hybrid 7	5.42 ($\pm .12$)
hybrid 8	2.75 ($\pm .08$)

¹host cell in all cases was *B. subtilis* BG2036.

It is evident that the hybrid enzymes fall into two basic classes. The first class, represented by hybrids 2,3,4 and 7 has Km's that are somewhat greater than that of either parental enzyme. The second class, represented by hybrids 6 and 8 has Km's that are intermediate between those of the parents.

These results show that the hybrid alkaline proteases have varying Km's for a particular synthetic substrate and that these differ from those of the parental enzymes. It is expected that determination of Km's using other synthetic substrates would also give a range of results and might also show varying favored substrates for the various hybrid enzymes.

EXAMPLE 7

In another preferred embodiment plasmids containing hybrid alpha amylase DNA sequences are selected by the post recombination transcription a tetracycline resistance determinant following excision of a transcription terminator as a result of homologous recombination between two parental alpha amylase DNA sequences.

A functional promoter is operably linked to *B. licheniformis* alpha amylase DNA sequences. A transcriptional terminator is placed 3' to this gene and 5' to DNA sequences encoding *B. stearothermophilus* alpha amylase. A tetracycline resistance gene lacking its own promoter is placed just 3' to the *B. stearothermophilus* DNA sequence. Cells containing a plasmid with these characteristics would be sensitive to tetracycline because transcriptional read-through from the upstream active promoter is prevented by the transcription terminator. However if recombination between the two alpha amylase DNA sequences occurs the terminator will be excised thus allowing transcription of the tetracycline resistance gene. Cells containing plasmids in which this homologous recombination has occurred can be selected by resistance to tetracycline thus eliminating all background from unrecombined plasmids. This method is completely applicable for recombining any two homologous gene fragments.

In order to use this method for selection of recombinant alpha amylase genes derived from the parental genes of *B. licheniformis* and *B. stearothermophilus* a plasmid is constructed as shown in Figure 8. Plasmid pBS42BL which contains the complete *B. licheniformis* alpha amylase gene is cleaved with EcoRI and HindIII. The smaller fragment (fragment A) is isolated. Plasmid pUC13 is cleaved the EcoRI and PstI and the larger fragment (fragment C) is isolated. Two synthetic oligonucleotides are synthesized and then heated to 95°C and cooled to 23°C to allow annealing. The resulting fragment (fragment B) contains the *E. coli* trp transcription terminator (boxed) flanked on the 5' end by a HindIII site and on the 3' end by SalI, Pvul, and PstI sites. Fragments A, B, and C are joined by ligation and used to transform *E. coli* 294. Ampicillin resistant colonies contain the plasmid designated pUC13BL. This plasmid is digested completely with Sall and partially with Pvul. Fragment D is isolated. Plasmid pUC13BS is cleaved with TaqI and BstXI and the fragment (fragment E) is isolated. The same plasmid is cleaved with BstXI and Pvul and the smaller fragment (fragment F) is isolated. Fragments, D, E, and F are joined by ligation and used to transform *E. coli* 294. Ampicillin resistant transformants contain plasmid pUC13BLBS. This plasmid contains the entire *B. licheniformis* alpha amylase gene including its native promoter followed by the *E. coli* transcription terminator which is then followed by the coding sequence of the *B. stearothermophilus* gene which is complete except for the first eight codons. Plasmid pUC13BLBS is then cleaved with EcoRI and BstXI and

the smaller fragment (fragment G) isolated. This plasmid is also cleaved with *Bst*XI and *Hind*III and the fragment H isolated. The plasmid pBR322 is cleaved with *Eco*RI and *Hind*III and the larger vector fragment (fragment I) isolated. Fragments G, H, and I are joined by ligation and transformed into *E. coli* 294. Ampicillin resistant transformants contain plasmid pBR322BLBSTCS. This plasmid differs most significantly from 5 *PUC13BLBS* by the fusion of the coding region and ribosome binding site of the tetracycline resistance gene to the 3' end of the *B. stearothermophilus* alpha amylase coding region.

The replication of pBR322BSBLTCS in *rec A* positive *E. coli* 294 results in the excision of the transcription terminator by homologous recombination between the two alpha amylase DNA sequences. Expression of this recombinant plasmid results in transcription from the *B. licheniformis* alpha amylase gene 10 promoter through the hybrid alpha amylase gene into the tetracycline resistance gene resulting in a polycistronic mRNA which is translated to give both the hybrid alpha amylase and the tetracycline resistance protein. Thus transformants containing such recombined plasmids can be selected by retransformation and selection on LB agar plates containing 5ug/ml tetracycline.

Although the foregoing refers to particular preferred embodiments, it will be understood that the present 15 invention is not so limited. It will occur to those ordinarily skilled in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention.

The references grouped in the following bibliography and respectively cited parenthetically by number in the foregoing text, are hereby incorporated by reference.

20

BIBLIOGRAPHY

1. Goeddel, et al., *Nature* 281, 544-548 (1979)
2. Pennica, et al., *Nature* 301, 214-221 (1983)
- 25 3. Talmadge, et al., *P.N.A.S. USA* 77(7), 3988-3992 (1980)
4. Weissman, EPO Publication No. 0032134 published July 15, 1981.
5. Weber, et al., *Nucleic Acids Res.* 11, 5661 (1983)
6. Lawn, et al., *Nucleic Acids Res.* 9, 6103 (1981)
7. Goeddel, et al., *Nucleic Acids Res.* 8, 4057 (1980)
- 30 8. Maniatis, et al. in: *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, p. 146 (1982)
9. Mandel, et al., *J. Mol. Biol.* 53, 154 (1970)
10. Anagnostopolous, et al., *J. Bact.* 81, 791 (1961)
11. Crea P.N.A.S. USA 75, 5765-5769 (1978)
- 35 12. Maniatis, et al. in: *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, p. 90 (1982)
13. Karn, et al. in: *Methods in Enzymology* 101, 3-19 (1983)
14. Hohn in: *Methods in Enzymology* 68, 229 (1979)
15. Karn, et al., *P.N.A.S. USA* 77, 5172-5176 (1980)
- 40 16. Cornelis, et al., *Molec. Gen. Genet.* 186, 507-511 (1982)
17. Wells, et al., *Nuc. Acids Res.* 11, 7911-7925 (1983)
18. Backman, et al., *P.N.A.S. USA* 73, 4174-4178 (1976)
19. Messing in: *Third Cleveland Symposium on Macromolecules: Recombinant DNA*, ed. A. Walton, Elsevier, Amsterdam, 143-153 (1981)
- 45 20. Southern, *J. Mol. Biol.* 98, 503-517 (1975)
21. Sanger, et al., *P.N.A.S. USA* 74, 5463-5467 (1977)
22. Maniatis, et al., *Cell* 15, 687-701 (1978)
23. Anderson, et al., *Nucleic Acids Res.* 8, 1731 (1980)
24. Maniatis, et al. in: *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold 50 Spring Harbor, New York, p. 370 (1982)
25. Bolivar, et al., *Gene* 2, 95-113 (1977)
26. Viera, et al., *Gene* 19, 259 (1982)
27. Maniatis, et al. in: *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, p. 387 (1982)
- 55 28. Wallace, et al., *Gene* 16, 21-26 (1981)
29. Koshland, et al., *Cell* 20, 749-760 (1980)
30. Jarrett, et al., *J. Biol. Chem.* 253, 4676 (1978)
31. Bradford, *Anal. Biochem.* 72, 248 (1976)

32. Stahl, et al., J. Bacteriol. 158, 411-418 (1984)
 33. Wells, et al., Nuc. Acids Res. 11, 7911-7925 (1983)
 34. Richardson in: Procedures in Nucleic Acid Research, G.L. Cantoni and D.R. Davies, eds., 2:815-828.
 Harper and Row, New York (1971)
- 5 35. Beggs, Nature 275, 104-109 (1978)
 36. Hynes, et al., Mol. Cell. Biol. 3, 1430-1439 (1983)
 37. Mulligan, et al., Science 209, 1422-1427 (1980)
 38. Renaut, et al., Gene 15, 81 (1981)
 39. Russell, et al., Gene 20, 23 (1982)
- 10 40. de Boer, et al., P.N.A.S. USA 80, 21 (1983)
 41. Takkinen, et al., J. Biol. Chem. 258, 1007-1013 (1983)
 42. Holland, et al., J. Biol. Chem. 255, 2596-2605 (1980)
 43. Penttila, et al., Molec. Genet. 194, 494-499 (1984)
 44. Bott, et al., EPO Publication No. 130756 published January 9, 1985.

15 **Claims****Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. A process for producing a hybrid DNA sequence comprising:
 forming a circular vector comprising a replicable DNA sequence, a first DNA sequence encoding the amino-terminal portion of a hybrid polypeptide, a second DNA sequence encoding the carboxy-terminal portion of said hybrid polypeptide and a third DNA sequence between said first and said second DNA sequences;
 transforming a rec positive microorganism with said vector to produce a cell population containing a multiplicity of said circular vector and permitting cross-over recombination of at least one of said vectors to excise said third DNA sequence to form a recombinant circular vector having a hybrid DNA sequence comprising said first and said second DNA sequences encoding said hybrid polypeptide, this cross-over recombination being initiated by at least partially homologous DNA sequences.
2. A process as claimed in Claim 1 wherein said third DNA sequence includes at least one unique restriction site and the process comprises the further steps of:
 (a) isolating said circular vector and said recombinant circular vector from said cell population;
 (b) treating said isolated circular vector and said recombinant circular vector with a restriction endonuclease specific for said one unique restriction site in said third DNA sequence to linearize said circular vector and;
 (c) exposing a second microorganism to said linearized vector and said recombinant circular vector and transforming said second microorganism with said recombinant circular vector.
3. A process as claimed in Claim 1 wherein said first DNA sequence comprises a functional promoter operably linked to the sequence encoding the amino-terminal portion of said hybrid polypeptide which corresponds to a first part of a first parental polypeptide sequence, said second DNA sequence encodes the carboxy-terminal portion of said hybrid polypeptide which corresponds to a first part of a second parental polypeptide sequence and said third DNA sequence encodes a second part of said first parental polypeptide sequence and a second part of said second parental polypeptide sequence.
4. A process as claimed in any one of Claims 1 to 3 further comprising the step of identifying the second microorganism which is transformed with the recombinant vector by detecting the absence of the third DNA sequence.
5. A process as claimed in any one of Claims 1 to 4 wherein the hybrid DNA sequence encodes a hybrid enzyme.
6. A process as claimed in any preceding claim wherein the hybrid enzyme is a hybrid amylase.
7. A process as claimed in any one of Claim 1 to 5 wherein the hybrid enzyme is a hybrid protease.
8. A process as claimed in Claim 6 wherein said first parental polypeptide sequence is all or part of the alpha amylase of B. stearothermophilus, said first part of said first parental polypeptide sequence is all

or part of an amino-terminal portion of said B. stearothermophilus alpha amylase, said second parental polypeptide sequence is the alpha amylase of B. licheniformis and said first part of said second parental polypeptide sequence is a carboxy-terminal portion of said B. licheniformis alpha amylase.

- 5 9. A process as claimed in Claim 7 wherein said first parental polypeptide sequence is all or part of the alkaline protease of B. subtilis, said first part of said first parental polypeptide sequence is an amino-terminal portion of said B. subtilis alkaline protease, said second parental polypeptide sequence is all or part of the alkaline protease of B. amyloliquifaciens and said first part of said second parental polypeptide sequence is a carboxy-terminal portion of said B. amyloliquifaciens alkaline protease.
- 10 10. A process for producing a hybrid polypeptide comprising producing a hybrid DNA sequence as claimed in any one of claims 1 to 9 and further comprising transcribing the hybrid DNA sequence to produce a hybrid RNA sequence and translating the hybrid RNA sequence to produce the hybrid polypeptide.
- 15 11. A process for producing an enzymatically active hybrid enzyme comprising producing a hybrid DNA sequence as claimed in any one of claims 1 to 9 and further comprising transcribing the hybrid DNA sequence to produce a hybrid RNA sequence and translating the hybrid RNA sequence to produce the enzymatically active hybrid enzyme.
- 20 12. An enzymatically active hybrid amylase comprising an amino-terminal sequence derived from a first parental amylase and a carboxy-terminal sequence derived from a second parental amylase, wherein said amino-terminal and said carboxy-terminal sequences are joined in a region wherein the underlying hybrid DNA encoding said hybrid amylase is derived as a result of a recombination event.
- 25 13. An enzymatically active hybrid protease comprising an amino-terminal sequence derived from a first parental protease and a carboxy-terminal sequence derived from a second parental protease, wherein said amino-terminal and said carboxy-terminal sequences are joined in a region wherein the underlying hybrid DNA encoding said hybrid protease is derived as a result of a recombination event.
- 30 14. An enzymatically active hybrid alpha amylase comprising an amino-terminal sequence derived from the alpha amylase of B. stearothermophilus and a carboxy-terminal sequence derived from the alpha amylase of B. licheniformis, wherein said amino-terminal and carboxy-terminal sequences are joined in a region wherein the underlying hybrid DNA encoding said hybrid alpha-amylase is derived as a result of a recombination event.
- 35 15. An enzymatically active hybrid alkaline protease comprising an amino-terminal sequence derived from the alkaline protease of B. subtilis and a carboxy-terminal sequence derived from the alkaline protease of B. amyloliquefaciens, wherein said amino-terminal and carboxy-terminal sequences are joined in a region wherein the underlying hybrid DNA encoding said hybrid alkaline protease is derived as a result of a recombination event.
- 40 16. A circular vector comprising a replicable DNA sequence, a first DNA sequence encoding the amino-terminal portion of a hybrid amylase or protease enzyme corresponding to a first part of a first parental amylase or protease sequence, a second DNA sequence encoding the carboxy-terminal portion of said hybrid amylase or protease corresponding to a first part of a second parental amylase or protease enzyme and a third DNA sequence between said first and said second DNA sequence, said third DNA sequence encoding a second part of said first parental amylase or protease enzyme and a second part of said second amylase or protease enzyme wherein said vector is capable of cross-over excision of said third DNA sequence, said cross-over excision being initiated by at least partially homologous DNA sequences between the first and second DNA sequence.
- 45 17. A circular vector comprising a replicable DNA sequence, a first DNA sequence encoding the amino-terminal portion of a hybrid amylase or protease enzyme corresponding to a first part of a first parental amylase or protease, a second DNA sequence encoding the carboxy-terminal portion of a hybrid amylase or protease corresponding to a first part of a second parental amylase or protease and a third DNA sequence between said first and said second DNA sequences, said third DNA sequence comprising at least one unique restriction site wherein said vector is capable of cross-over excision of

said third DNA sequence, said cross-over excision being initiated by at least partially homologous DNA sequences between the first and second DNA sequence.

- 5 18. A hybrid amylase or protease enzyme obtainable from a vector according to claim 16 or 17, and which is enzymatically active.
- 10 19. A circular vector comprising a replicable DNA sequence, a first DNA sequence encoding the amino-terminal portion of a hybrid polypeptide, a second DNA sequence encoding the carboxy-terminal portion of a hybrid polypeptide and a third DNA sequence between said first and said second DNA sequences, said third DNA sequence comprising a DNA sequence which prevents expression of said second DNA sequence wherein said vector is capable of cross-over excision of said third DNA sequence, said cross-over excision being initiated by at least partially homologous DNA sequences between the first and second DNA sequence.
- 15 20. A circular vector comprising a replicable DNA sequence, a first DNA sequence encoding the amino-terminal portion of a hybrid polypeptide, a second DNA sequence encoding the carboxy-terminal portion of a hybrid polypeptide, a third DNA sequence between said first and said second DNA sequences, said third DNA sequence comprising a DNA sequence which prevents the expression of said second DNA sequence and a fourth DNA sequence 3' to said second DNA sequence, said fourth DNA sequence encoding a defined selection characteristic wherein said vector is capable of cross-over excision of said third DNA sequence, said cross-over excision being initiated by at least partially homologous DNA sequences between the first and second DNA sequence.

Claims for the following Contracting State : AT

- 25 1. A process for producing a hybrid DNA sequence comprising:
 forming a circular vector comprising a replicable DNA sequence, a first DNA sequence encoding the amino-terminal portion of a hybrid polypeptide, a second DNA sequence encoding the carboxy-terminal portion of said hybrid polypeptide and a third DNA sequence between said first and said second DNA sequences;
 transforming a rec positive microorganism with said vector to produce a cell population containing a multiplicity of said circular vector and permitting cross-over recombination of at least one of said vectors to excise said third DNA sequence to form a recombinant circular vector having a hybrid DNA sequence comprising said first and said second DNA sequences encoding said hybrid polypeptide, this cross-over recombination being initiated by at least partially homologous DNA sequences.
- 30 2. A process as claimed in Claim 1 wherein said third DNA sequence includes at least one unique restriction site and the process comprises the further steps of:
 (a) isolating said circular vector and said recombinant circular vector from said cell population;
 (b) treating said isolated circular vector and said recombinant circular vector with a restriction endonuclease specific for said one unique restriction site in said third DNA sequence to linearize said circular vector and;
 (c) exposing a second microorganism to said linearized vector and said recombinant circular vector and transforming said second microorganism with said recombinant circular vector.
- 35 45 3. A process as claimed in Claim 1 wherein said first DNA sequence comprises a functional promoter operably linked to the sequence encoding the amino-terminal portion of said hybrid polypeptide which corresponds to a first part of a first parental polypeptide sequence, said second DNA sequence encodes the carboxy-terminal portion of said hybrid polypeptide which corresponds to a first part of a second parental polypeptide sequence and said third DNA sequence encodes a second part of said first parental polypeptide sequence and a second part of said second parental polypeptide sequence.
- 40 50 4. A process as claimed in any one of Claims 1 to 3 further comprising the step of identifying the second microorganism which is transformed with the recombinant vector by detecting the absence of the third DNA sequence.
- 45 55 5. A process as claimed in any one of Claims 1 to 4 wherein the hybrid DNA sequence encodes a hybrid enzyme.

6. A process as claimed in any preceding claim wherein the hybrid enzyme is a hybrid amylase.
7. A process as claimed in any one of Claim 1 to 5 wherein the hybrid enzyme is a hybrid protease.
- 5 8. A process as claimed in Claim 6 wherein said first parental polypeptide sequence is all or part of the alpha amylase of B. stearothermophilus, said first part of said first parental polypeptide sequence is all or part of an amino-terminal portion of said B. stearothermophilus alpha amylase, said second parental polypeptide sequence is the alpha amylase of B. licheniformis and said first part of said second parental polypeptide sequence is a carboxy-terminal portion of said B. licheniformis alpha amylase.
- 10 9. A process as claimed in Claim 7 wherein said first parental polypeptide sequence is all or part of the alkaline protease of B. subtilis, said first part of said first parental polypeptide sequence is an amino-terminal portion of said B. subtilis alkaline protease, said second parental polypeptide sequence is all or part of the alkaline protease of B. amyloliquifaciens and said first part of said second parental polypeptide sequence is a carboxy-terminal portion of said B. amyloliquifaciens alkaline protease.
- 15 10. A process for producing a hybrid polypeptide comprising producing a hybrid DNA sequence as claimed in any one of claims 1 to 9 and further comprising transcribing the hybrid DNA sequence to produce a hybrid RNA sequence and translating the hybrid RNA sequence to produce the hybrid polypeptide.
- 20 11. A process for producing an enzymatically active hybrid enzyme comprising producing a hybrid DNA sequence as claimed in any one of claims 1 to 9 and further comprising transcribing the hybrid DNA sequence to produce a hybrid RNA sequence and translating the hybrid RNA sequence to produce the enzymatically active hybrid enzyme.
- 25

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LU, NL, SE

- 30 1. Verfahren zur Herstellung einer DNA-Hybridsequenz umfassend:
Bilden eines zirkulären Vektors, der eine replizierbare DNA-Sequenz, eine für den aminoterminalen Abschnitt eines Hybridpolypeptids codierende erste DNA-Sequenz, eine für den carboxyterminalen Abschnitt des Hybridpolypeptids codierende zweite DNA-Sequenz und eine dritte DNA-Sequenz zwischen der ersten und der zweiten DNA-Sequenz enthält,
- 35 Transformieren eines rec-positiven Mikroorganismus mit diesem Vektor, um eine Zellpopulation zu erzeugen, die eine Vielzahl dieses zirkulären Vektors umfaßt, und ermöglichen einer Crossover-Rekombination von mindestens einem der Vektoren, um die dritte DNA-Sequenz herauszuschneiden, so daß ein rekombinierter zirkulärer Vektor mit einer DNA-Hybridsequenz gebildet wird, die die für das Hybridpolypeptid codierende erste und zweite DNA-Sequenz umfaßt, wobei diese Crossover-Rekombination durch mindestens teilweise homologe DNA-Sequenzen initiiert wird.
- 40
2. Verfahren nach Anspruch 1, worin die dritte DNA-Sequenz mindestens eine singuläre Restriktionsstelle enthält und das Verfahren die weiteren Schritte umfaßt:
 - (a) Isolieren des zirkulären Vektors und des rekombinierten zirkulären Vektors aus der Zellpopulation,
 - (b) Behandeln des isolierten zirkulären Vektors und des rekombinierten zirkulären Vektors mit einer Restriktionsendonuklease, die spezifisch für die eine singuläre Restriktionsstelle in der dritten DNA-Sequenz ist, um den zirkulären Vektor zu linearisieren und
 - (c) Inkontaktrbringen eines zweiten Mikroorganismus mit dem linearisierten Vektor und dem rekombinierten zirkulären Vektor und Transformieren des zweiten Mikroorganismus mit dem rekombinierten zirkulären Vektor.
- 45
3. Verfahren nach Anspruch 1, worin die erste DNA-Sequenz einen funktionellen Promotor umfaßt, der operativ mit der für den aminoterminalen Abschnitt des Hybridpolypeptids codierenden Sequenz verknüpft ist, die einem ersten Teil einer ersten Polypeptidausgangssequenz entspricht, die zweite DNA-Sequenz für den carboxyterminalen Abschnitt des Hybridpolypeptids codiert, das einem ersten Teil einer zweiten Polypeptidausgangssequenz entspricht, und die dritte DNA-Sequenz für einen zweiten Teil der ersten Polypeptidausgangssequenz und einen zweiten Teil der zweiten Polypeptidaus-
- 50
- 55

gangssequenz codiert.

4. Verfahren nach einem der Ansprüche 1 bis 3, weiterhin umfassend den Schritt des Identifizierens des zweiten Mikroorganismus, der mit dem rekombinierten Vektor transformiert ist, durch Nachweis des Fehlens der dritten DNA-Sequenz.
5. Verfahren nach einem der Ansprüche 1 bis 4, worin die DNA-Hybridsequenz für ein Hybridenzym codiert.
10. 6. Verfahren nach einem der vorhergehenden Ansprüche, worin das Hybridenzym eine Hybridamylase ist.
7. Verfahren nach einem der Ansprüche 1 bis 5, worin das Hybridenzym eine Hybridprotease ist.
15. 8. Verfahren nach Anspruch 6, worin die erste Polypeptidausgangssequenz die gesamte oder ein Teil der α -Amylase von B. stearothermophilus ist, der erste Teil der ersten Polypeptidausgangssequenz vollständig oder teilweise ein aminoterminaler Abschnitt der B. stearothermophilus- α -Amylase ist, die zweite Polypeptidausgangssequenz die α -Amylase von B. licheniformis ist und der erste Teil der zweiten Polypeptidausgangssequenz ein carboxyterminaler Abschnitt der B. licheniformis- α -Amylase ist.
20. 9. Verfahren nach Anspruch 7, worin die erste Polypeptidausgangssequenz die gesamte oder ein Teil der Alkalischen Protease von B. subtilis ist, der erste Teil der ersten Polypeptidausgangssequenz ein aminoterminaler Abschnitt der Alkalischen Protease aus B. subtilis ist, die zweite Polypeptidausgangssequenz die gesamte oder ein Teil der Alkalischen Protease von B. amyloliquefaciens ist und der erste Teil der zweiten Polypeptidausgangssequenz ein carboxyterminaler Abschnitt der Alkalischen Protease von B. amyloliquefaciens ist.
25. 10. Verfahren zur Herstellung eines Hybridpolypeptids, umfassend die Herstellung einer DNA-Hybridsequenz nach einem der Ansprüche 1 bis 9 und weiterhin umfassend die Transkription der DNA-Hybridsequenz zur Erzeugung einer RNA-Hybridsequenz und die Translation der RNA-Hybridsequenz zur Erzeugung des Hybridpolypeptids.
30. 11. Verfahren zur Herstellung eines enzymatisch aktiven Hybridenzyms, umfassend die Herstellung einer DNA-Hybridsequenz nach einem der Ansprüche 1 bis 9 und weiterhin umfassend die Transkription der DNA-Hybridsequenz zur Erzeugung einer RNA-Hybridsequenz und die Translation der RNA-Hybridsequenz zur Erzeugung des enzymatisch aktiven Hybridenzyms.
35. 12. Enzymatisch aktive Hybridamylase, umfassend eine aus einer ersten Ausgangsamylose stammende aminotermrale Sequenz und eine aus einer zweiten Ausgangsamylose stammende carboxyterminale Sequenz, worin die aminotermrale und die carboxyterminale Sequenz in einer Region verknüpft sind, in der die zugrundeliegende, für die Hybridamylase codierende Hybrid-DNA als Ergebnis eines Rekombinationsvorgangs erhalten worden ist.
40. 13. Enzymatisch aktive Hybridprotease, umfassend eine aus einer ersten Ausgangsprotease stammende aminotermrale Sequenz und eine aus einer zweiten Ausgangsprotease stammende carboxyterminale Sequenz, worin die aminotermrale und die carboxyterminale Sequenz in einer Region verknüpft sind, worin die zugrundeliegende, für die Hybridprotease codierende Hybrid-DNA als Ergebnis eines Rekombinationsvorgangs erhalten worden ist.
45. 14. Enzymatisch aktive Hybrid- α -Amylase, umfassend eine aus der α -Amylase von B. stearothermophilus stammende aminotermrale Sequenz und eine aus der α -Amylase von B. licheniformis stammende carboxyterminale Sequenz, worin die aminotermrale und carboxyterminale Sequenz in einer Region verknüpft sind, in der die zugrundeliegende, für die Hybrid- α -Amylase codierende Hybrid-DNA als Ergebnis eines Rekombinationsvorgangs erhalten worden ist.
50. 15. Enzymatisch aktive Hybrid-Alkalische Protease, umfassend eine aus der Alkalischen Protease von B. subtilis stammende aminotermrale Sequenz und eine aus der Alkalischen Protease von B. amyloliquefaciens stammende carboxyterminale Sequenz, worin die aminotermrale und carboxyterminale Se-

quenz in einer Region verknüpft sind, in der die zugrundeliegende, für die Hybrid-Alkalische Protease codierende Hybrid-DNA als Ergebnis eines Rekombinationsvorgangs erhalten worden ist.

16. Zirkulärer Vektor, umfassend eine replizierbare DNA-Sequenz, eine erste DNA-Sequenz, die für den aminoterminalen Abschnitt eines Hybrid-Amylase- oder -Proteaseenzyms entsprechend einem ersten Teil einer ersten Ausgangs-Amylase- oder -Protease-Sequenz codiert, eine zweite DNA-Sequenz, die für den carboxyterminalen Abschnitt der Hybrid-Amylase oder -Protease entsprechend einem ersten Teil eines zweiten Ausgangs-Amylase- oder -Proteaseenzyms codiert, und eine dritte DNA-Sequenz zwischen der ersten und der zweiten DNA-Sequenz, wobei die dritte DNA-Sequenz für einen zweiten Teil des ersten Ausgangs-Amylase- oder -Proteaseenzyms und einen zweiten Teil des zweiten Amylase- oder Proteaseenzyms codiert, worin der Vektor zum Crossover-Herausschneiden der dritten DNA-Sequenz in der Lage ist, wobei das Crossover-Herausschneiden von mindestens teilweise homologen DNA-Sequenzen zwischen der ersten und zweiten DNA-Sequenz initiiert wird.
17. Zirkulärer Vektor, umfassend eine replizierbare DNA-Sequenz, eine erste DNA-Sequenz, die für den aminoterminalen Abschnitt eines Hybrid-Amylase- oder -Proteaseenzyms entsprechend einem ersten Teil einer ersten Ausgangs-Amylase oder -Protease codiert, eine zweite DNA-Sequenz, die für den carboxyterminalen Abschnitt einer Hybrid-Amylase oder -Protease entsprechend einem ersten Teil einer zweiten Ausgangs-Amylase oder -Protease codiert, und eine dritte DNA-Sequenz zwischen der ersten und der zweiten DNA-Sequenz, wobei die dritte DNA-Sequenz mindestens eine singuläre Restriktionsstelle umfaßt, worin der Vektor zu einem Crossover-Herausschneiden der dritten DNA-Sequenz in der Lage ist, wobei das Crossover-Herausschneiden von mindestens teilweise homologen DNA-Sequenzen zwischen der ersten und zweiten DNA-Sequenz initiiert wird.
18. Hybrid-Amylase- oder -Proteaseenzym, erhältlich aus einem Vektor nach Anspruch 16 oder 17, das enzymatisch aktiv ist.
19. Zirkulärer Vektor, umfassend eine replizierbare DNA-Sequenz, eine für den aminoterminalen Abschnitt eines Hybridpolypeptids codierende erste DNA-Sequenz, eine für den carboxyterminalen Abschnitt eines Hybridpolypeptids codierende zweite DNA-Sequenz und eine dritte DNA-Sequenz zwischen der ersten und zweiten DNA-Sequenz, wobei die dritte DNA-Sequenz eine DNA-Sequenz umfaßt, welche die Expression der zweiten DNA-Sequenz verhindert, worin der Vektor zum Crossover-Herausschneiden der dritten DNA-Sequenz in der Lage ist, wobei das Crossover-Herausschneiden von mindestens teilweise homologen DNA-Sequenzen zwischen der ersten und zweiten DNA-Sequenz initiiert wird.
20. Zirkulärer Vektor, umfassend eine replizierbare DNA-Sequenz, eine für den aminoterminalen Abschnitt eines Hybridpolypeptids codierende erste DNA-Sequenz, eine für den carboxyterminalen Abschnitt eines Hybridpolypeptids codierende zweite DNA-Sequenz, eine dritte DNA-Sequenz zwischen der ersten und der zweiten DNA-Sequenz, wobei die dritte DNA-Sequenz eine DNA-Sequenz enthält, welche die Expression der zweiten DNA-Sequenz verhindert, und eine vierte DNA-Sequenz 3'-seitig der zweiten DNA-Sequenz, wobei die vierte DNA-Sequenz für ein definiertes Selektionsmerkmal codiert, worin der Vektor zum Crossover-Herausschneiden der dritten DNA-Sequenz in der Lage ist, worin das Crossover-Herausschneiden von mindestens teilweise homologen DNA-Sequenzen zwischen der ersten und zweiten DNA-Sequenz initiiert wird.

45

Patentansprüche für folgenden Vertragsstaat : AT

1. Verfahren zur Herstellung einer DNA-Hybridsequenz umfassend:
Bilden eines zirkulären Vektors, der eine replizierbare DNA-Sequenz, eine für den aminoterminalen Abschnitt eines Hybridpolypeptids codierende erste DNA-Sequenz, eine für den carboxyterminalen Abschnitt des Hybridpolypeptids codierende zweite DNA-Sequenz und eine dritte DNA-Sequenz zwischen der ersten und der zweiten DNA-Sequenz enthält,
Transformieren eines rec-positiven Mikroorganismus mit diesem Vektor, um eine Zellpopulation zu erzeugen, die eine Vielzahl dieses zirkulären Vektors umfaßt, und ermöglichen einer Crossover-Rekombination von mindestens einem der Vektoren, um die dritte DNA-Sequenz herauszuschneiden, so daß ein rekombinierter zirkulärer Vektor mit einer DNA-Hybridsequenz gebildet wird, die die für das Hybridpolypeptid codierende erste und zweite DNA-Sequenz umfaßt, wobei diese Crossover-Rekombination durch mindestens teilweise homologe DNA-Sequenzen initiiert wird.

2. Verfahren nach Anspruch 1, worin die dritte DNA-Sequenz mindestens eine singuläre Restriktionsstelle enthält und das Verfahren die weiteren Schritte umfaßt:
 - (a) Isolieren des zirkulären Vektors und des rekombinierten zirkulären Vektors aus der Zellpopulation,
 - 5 (b) Behandeln des isolierten zirkulären Vektors und des rekombinierten zirkulären Vektors mit einer Restriktionsendonuklease, die spezifisch für die eine singuläre Restriktionsstelle in der dritten DNA-Sequenz ist, um den zirkulären Vektor zu linearisieren und
 - (c) Inkontaktbringen eines zweiten Mikroorganismus mit dem linearisierten Vektor und dem rekombinierten zirkulären Vektor und Transformieren des zweiten Mikroorganismus mit dem rekombinierten zirkulären Vektor.
- 10 3. Verfahren nach Anspruch 1, worin die erste DNA-Sequenz einen funktionellen Promotor umfaßt, der operativ mit der für den aminoterminalen Abschnitt des Hybridpolypeptids codierenden Sequenz verknüpft ist, die einem ersten Teil einer ersten Polypeptidausgangssequenz entspricht, die zweite DNA-Sequenz für den carboxyterminalen Abschnitt des Hybridpolypeptids codiert, das einem ersten Teil einer zweiten Polypeptidausgangssequenz entspricht, und die dritte DNA-Sequenz für einen zweiten Teil der ersten Polypeptidausgangssequenz und einen zweiten Teil der zweiten Polypeptidausgangssequenz codiert.
- 15 4. Verfahren nach einem der Ansprüche 1 bis 3, weiterhin umfassend den Schritt des Identifizierens des zweiten Mikroorganismus, der mit dem rekombinierten Vektor transformiert ist, durch Nachweis des Fehlens der dritten DNA-Sequenz.
- 20 5. Verfahren nach einem der Ansprüche 1 bis 4, worin die DNA-Hybridsequenz für ein Hybridenzym codiert.
- 25 6. Verfahren nach einem der vorhergehenden Ansprüche, worin das Hybridenzym eine Hybridamylase ist.
7. Verfahren nach einem der Ansprüche 1 bis 5, worin das Hybridenzym eine Hybridprotease ist.
- 30 8. Verfahren nach Anspruch 6, worin die erste Polypeptidausgangssequenz die gesamte oder ein Teil der α -Amylase von B. stearothermophilus ist, der erste Teil der ersten Polypeptidausgangssequenz vollständig oder teilweise ein aminoterminaler Abschnitt der B. stearothermophilus- α -Amylase ist, die zweite Polypeptidausgangssequenz die α -Amylase von B. licheniformis ist und der erste Teil der zweiten Polypeptidausgangssequenz ein carboxyterminaler Abschnitt der B. licheniformis- α -Amylase ist.
- 35 9. Verfahren nach Anspruch 7, worin die erste Polypeptidausgangssequenz die gesamte oder ein Teil der Alkalischen Protease von B. subtilis ist, der erste Teil der ersten Polypeptidausgangssequenz ein aminoterminaler Abschnitt der Alkalischen Protease aus B. subtilis ist, die zweite Polypeptidausgangssequenz die gesamte oder ein Teil der Alkalischen Protease von B. amyloliquefaciens ist und der erste Teil der zweiten Polypeptidausgangssequenz ein carboxyterminaler Abschnitt der Alkalischen Protease von B. amyloliquefaciens ist.
- 40 45 10. Verfahren zur Herstellung eines Hybridpolypeptids, umfassend die Herstellung einer DNA-Hybridsequenz nach einem der Ansprüche 1 bis 9 und weiterhin umfassend die Transkription der DNA-Hybridsequenz zur Erzeugung einer RNA-Hybridsequenz und die Translation der RNA-Hybridsequenz zur Erzeugung des Hybridpolypeptids.
- 50 11. Verfahren zur Herstellung eines enzymatisch aktiven Hybridenzyms, umfassend die Herstellung einer DNA-Hybridsequenz nach einem der Ansprüche 1 bis 9 und weiterhin umfassend die Transkription der DNA-Hybridsequenz zur Erzeugung einer RNA-Hybridsequenz und die Translation der RNA-Hybridsequenz zur Erzeugung des enzymatisch aktiven Hybridenzyms.

Revendications**Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Procédé de préparation d'une séquence hybride d'ADN, comprenant :
 - la formation d'un vecteur circulaire comprenant une séquence d'ADN réplicable, une première séquence d'ADN codant la portion amino-terminale d'un polypeptide hybride, une deuxième séquence d'ADN codant la portion carboxy-terminale dudit polypeptide hybride, et une troisième séquence d'ADN située entre lesdites première et deuxième séquences d'ADN;
 - la transformation d'un micro-organisme rec positif avec ledit vecteur pour produire une population de cellules contenant une multiplicité dudit vecteur circulaire et permettant la recombinaison croisée d'au moins un desdits vecteurs pour exciser ladite troisième séquence d'ADN pour former un vecteur circulaire recombiné ayant une séquence hybride d'ADN comprenant lesdites première et deuxième séquences d'ADN codant ledit polypeptide hybride, cette recombinaison croisée étant amorcée par des séquences d'ADN au moins partiellement homologues.
2. Procédé tel que revendiqué dans la revendication 1, dans lequel ladite troisième séquence d'ADN comprend au moins un site de restriction unique, et le procédé comprend les étapes complémentaires consistant à:
 - (a) isoler ledit vecteur circulaire et ledit vecteur circulaire recombiné de ladite population de cellules ;
 - (b) traiter ledit vecteur circulaire isolé et ledit vecteur circulaire recombiné avec une endonucléase de restriction spécifique pour ledit site de restriction unique dans ladite troisième séquence d'ADN, pour linéariser ledit vecteur circulaire ; et
 - (c) exposer un deuxième micro-organisme audit vecteur linéarisé et audit vecteur circulaire recombiné et transformer ledit deuxième micro-organisme avec ledit vecteur circulaire recombiné.
3. Procédé tel que revendiqué dans la revendication 1, dans lequel ladite première séquence d'ADN comprend un promoteur fonctionnel lié efficacement à la séquence codant la portion amino-terminale dudit polypeptide hybride qui correspond à une première partie d'une première séquence parentale de polypeptide, ladite deuxième séquence d'ADN code la portion carboxy-terminale dudit polypeptide hybride qui correspond à une première partie d'une deuxième séquence parentale de polypeptide, et ladite troisième séquence d'ADN code une deuxième partie de ladite première séquence parentale de polypeptide et une deuxième partie de ladite deuxième séquence parentale de polypeptide.
4. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 3, comprenant, en outre, l'étape d'identification du deuxième micro-organisme qui est transformé avec le vecteur recombiné, par détection de l'absence de la troisième séquence d'ADN.
5. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 4, dans lequel la séquence hybride d'ADN code une enzyme hybride.
6. Procédé tel que revendiqué dans l'une quelconque des revendications précédentes, dans lequel l'enzyme hybride est une amylase hybride.
7. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 5, dans lequel l'enzyme hybride est une protéase hybride.
8. Procédé tel que revendiqué dans la revendication 6, dans lequel ladite première séquence parentale de polypeptide est l'ensemble ou une partie de l'alpha-amylase de *B. stearothermophilus*, ladite première partie de ladite première séquence parentale de polypeptide est l'ensemble ou une partie d'une portion amino-terminale de ladite alpha-amylase de *B. stearothermophilus*, ladite deuxième séquence parentale de polypeptide est l'alpha-amylase de *B. licheniformis*, et ladite première partie de ladite deuxième séquence parentale de polypeptide est une portion carboxyterminale de ladite alpha-amylase de *B. licheniformis*.
9. Procédé tel que revendiqué dans la revendication 7, dans lequel ladite première séquence parentale de polypeptide est l'ensemble ou une partie de la protéase alcaline de *B. subtilis*, ladite première partie de ladite première séquence parentale de polypeptide est une portion amino-terminale de ladite protéase

alcaline de B. subtilis, ladite deuxième séquence parentale de polypeptide est l'ensemble ou une partie de la protéase alcaline de B. amyloliquefaciens, et ladite première partie de ladite deuxième séquence parentale de polypeptide est une portion carboxy-terminale de ladite protéase alcaline de B. amyloliquefaciens.

- 5 **10.** Procédé de préparation d'un polypeptide hybride, comprenant la préparation d'une séquence hybride d'ADN telle que revendiquée dans l'une quelconque des revendications 1 à 9 et comprenant, en outre, la transcription de la séquence hybride d'ADN pour produire une séquence hybride d'ARN et la traduction de la séquence hybride d'ARN pour produire le polypeptide hybride.
- 10 **11.** Procédé de préparation d'une enzyme hybride enzymatiquement active, comprenant la préparation d'une séquence hybride d'ADN telle que revendiquée dans l'une quelconque des revendications 1 à 9 et comprenant, en outre, la transcription de la séquence hybride d'ADN pour produire une séquence hybride d'ARN et la traduction de la séquence hybride d'ARN pour produire l'enzyme hybride enzymatiquement active.
- 15 **12.** Amylase hybride enzymatiquement active, comprenant une séquence amino-terminale provenant d'une première amylase parentale et une séquence carboxy-terminale provenant d'une deuxième amylase parentale, dans laquelle lesdites séquences amino-terminale et carboxy-terminale sont reliées dans une 20 région où l'ADN hybride situé au-dessous, codant ladite amylase hybride, est le résultat d'un phénomène de recombinaison.
- 25 **13.** Protéase hybride enzymatiquement active, comprenant une séquence amino-terminale provenant d'une première protéase parentale et une séquence carboxy-terminale provenant d'une deuxième protéase parentale, dans laquelle lesdites séquences amino-terminale et carboxy-terminale sont reliées dans une 30 région où l'ADN hybride situé au-dessous, codant ladite protéase hybride, est le résultat d'un phénomène de recombinaison.
- 35 **14.** Alpha-amylase hybride enzymatiquement active, comprenant une séquence amino-terminale provenant de l'alpha-amylase de B. stearothermophilus et une séquence carboxy-terminale provenant de l'alpha-amylase de B. licheniformis, dans laquelle lesdites séquences amino-terminale et carboxy-terminale sont reliées dans une région où l'ADN hybride situé au-dessous, codant ladite alpha-amylase hybride, est le résultat d'un phénomène de recombinaison.
- 40 **15.** Protéase alcaline hybride enzymatiquement active, comprenant une séquence amino-terminale provenant de la protéase alcaline de B. subtilis et une séquence carboxy-terminale provenant de la protéase alcaline de B. amyloliquefaciens, dans laquelle lesdites séquences amino-terminale et carboxy-terminale sont reliées dans une région où l'ADN hybride situé au-dessous, codant ladite protéase alcaline hybride, est le résultat d'un phénomène de recombinaison.
- 45 **16.** Vecteur circulaire comprenant une séquence d'ADN répliable, une première séquence d'ADN codant la portion amino-terminale d'une enzyme hybride amylase ou protéase correspondant à une première partie d'une première séquence d'amylase ou de protéase parentale, une deuxième séquence d'ADN codant la portion carboxy-terminale de ladite amylase ou protéase hybride, correspondant à une première partie d'une deuxième enzyme parentale amylase ou protéase, et une troisième séquence d'ADN située entre lesdites première et deuxième séquences d'ADN, ladite troisième séquence d'ADN codant une deuxième partie de ladite première enzyme parentale amylase ou protéase et une deuxième partie de ladite deuxième enzyme amylase ou protéase, où ledit vecteur est capable d'une excision croisée de ladite séquence d'ADN, ladite excision croisée étant amorcée par des séquences d'ADN au moins partiellement homologues, situées entre les première et deuxième séquences d'ADN.
- 50 **17.** Vecteur circulaire comprenant une séquence d'ADN répliable, une première séquence d'ADN codant la portion amino-terminale d'une enzyme hybride amylase ou protéase, correspondant à une première partie d'une première amylase ou protéase parentale, une deuxième séquence d'ADN codant la portion carboxy-terminale d'une amylase ou protéase hybride, correspondant à une première partie d'une deuxième amylase ou protéase parentale, et une troisième séquence d'ADN située entre lesdites première et deuxième séquences d'ADN, ladite troisième séquence d'ADN comprenant au moins un site de restriction unique où ledit vecteur est capable d'une excision croisée de ladite troisième

séquence d'ADN, ladite excision croisée étant amorcée par des séquences d'ADN au moins partiellement homologues, situées entre les première et deuxième séquences d'ADN.

18. Enzyme hybride amylase ou protéase, pouvant être obtenue à partir d'un vecteur selon la revendication 5 ou 17 et qui est enzymatiquement active.
19. Vecteur circulaire comprenant une séquence d'ADN réplicable, une première séquence d'ADN codant la portion amino-terminale d'un polypeptide hybride, une deuxième séquence d'ADN codant la portion carboxy-terminale d'un polypeptide hybride, et une troisième séquence d'ADN située entre lesdites 10 premières et deuxièmes séquences d'ADN, ladite troisième séquence d'ADN comprenant une séquence d'ADN qui empêche l'expression de ladite deuxième séquence d'ADN, où ledit vecteur est capable d'une excision croisée de ladite troisième séquence d'ADN, ladite excision croisée étant amorcée par des séquences d'ADN au moins partiellement homologues, situées entre les premières et deuxièmes séquences d'ADN.
20. Vecteur circulaire comprenant une séquence d'ADN réplicable, une première séquence d'ADN codant la portion amino-terminale d'un polypeptide hybride, une deuxième séquence d'ADN codant la portion carboxy-terminale d'un polypeptide hybride, une troisième séquence d'ADN située entre lesdites premières et deuxièmes séquences d'ADN, ladite troisième séquence d'ADN comprenant une séquence d'ADN qui empêche l'expression de ladite deuxième séquence d'ADN, et une quatrième séquence d'ADN 3' sur ladite deuxième séquence d'ADN, ladite quatrième séquence d'ADN codant une caractéristique de sélection définie, où ledit vecteur est capable d'une excision croisée de ladite troisième séquence d'ADN, ladite excision croisée étant amorcée par des séquences d'ADN au moins partiellement homologues, situées entre lesdites premières et deuxièmes séquences d'ADN.

Revendications pour l'Etat contractant suivant : AT

1. Procédé de préparation d'une séquence hybride d'ADN, comprenant :
 - la formation d'un vecteur circulaire comprenant une séquence d'ADN réplicable, une première séquence d'ADN codant la portion amino-terminale d'un polypeptide hybride, une deuxième séquence d'ADN codant la portion carboxy-terminale dudit polypeptide hybride, et une troisième séquence d'ADN située entre lesdites premières et deuxièmes séquences d'ADN;
 - la transformation d'un micro-organisme rec positif avec ledit vecteur pour produire une population de cellules contenant une multiplicité dudit vecteur circulaire et permettant la recombinaison croisée d'au moins un desdits vecteurs pour exciser ladite troisième séquence d'ADN pour former un vecteur circulaire recombiné ayant une séquence hybride d'ADN comprenant lesdites premières et deuxièmes séquences d'ADN codant ledit polypeptide hybride, cette recombinaison croisée étant amorcée par des séquences d'ADN au moins partiellement homologues.
2. Procédé tel que revendiqué dans la revendication 1, dans lequel ladite troisième séquence d'ADN comprend au moins un site de restriction unique, et le procédé comprend les étapes complémentaires consistant à:
 - (a) isoler ledit vecteur circulaire et ledit vecteur circulaire recombiné de ladite population de cellules ;
 - (b) traiter ledit vecteur circulaire isolé et ledit vecteur circulaire recombiné avec une endonucléase de restriction spécifique pour ledit site de restriction unique dans ladite troisième séquence d'ADN, pour linéariser ledit vecteur circulaire ; et
 - (c) exposer un deuxième micro-organisme audit vecteur linéarisé et audit vecteur circulaire recombiné et transformer ledit deuxième micro-organisme avec ledit vecteur circulaire recombiné.
3. Procédé tel que revendiqué dans la revendication 1, dans lequel ladite première séquence d'ADN comprend un promoteur fonctionnel lié efficacement à la séquence codant la portion amino-terminale dudit polypeptide hybride qui correspond à une première partie d'une première séquence parentale de polypeptide, ladite deuxième séquence d'ADN code la portion carboxy-terminale dudit polypeptide hybride qui correspond à une première partie d'une deuxième séquence parentale de polypeptide, et ladite troisième séquence d'ADN code une deuxième partie de ladite première séquence parentale de polypeptide et une deuxième partie de ladite deuxième séquence parentale de polypeptide.

4. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 3, comprenant, en outre, l'étape d'identification du deuxième micro-organisme qui est transformé avec le vecteur recombiné, par détection de l'absence de la troisième séquence d'ADN.
5. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 4, dans lequel la séquence hybride d'ADN code une enzyme hybride.
6. Procédé tel que revendiqué dans l'une quelconque des revendications précédentes, dans lequel l'enzyme hybride est une amylase hybride.
- 10 7. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 5, dans lequel l'enzyme hybride est une protéase hybride.
8. Procédé tel que revendiqué dans la revendication 6, dans lequel ladite première séquence parentale de polypeptide est l'ensemble ou une partie de l'alpha-amylase de B. stearothermophilus, ladite première partie de ladite première séquence parentale de polypeptide est l'ensemble ou une partie d'une portion amino-terminale de ladite alpha-amylase de B. stearothermophilus, ladite deuxième séquence parentale de polypeptide est l'alpha-amylase de B. licheniformis, et ladite première partie de ladite deuxième séquence parentale de polypeptide est une portion carboxy-terminale de ladite alpha-amylase de B. licheniformis.
- 15 9. Procédé tel que revendiqué dans la revendication 7, dans lequel ladite première séquence parentale de polypeptide est l'ensemble ou une partie de la protéase alcaline de B. subtilis, ladite première partie de ladite première séquence parentale de polypeptide est une portion amino-terminale de ladite protéase alcaline de B. subtilis, ladite deuxième séquence parentale de polypeptide est l'ensemble ou une partie de la protéase alcaline de B. amyloliquefaciens, et ladite première partie de ladite deuxième séquence parentale de polypeptide est une portion carboxy-terminale de ladite protéase alcaline de B. amyloliquefaciens.
- 20 30 10. Procédé de préparation d'un polypeptide hybride, comprenant la préparation d'une séquence hybride d'ADN telle que revendiquée dans l'une quelconque des revendications 1 à 9 et comprenant, en outre, la transcription de la séquence hybride d'ADN pour produire une séquence hybride d'ARN et la traduction de la séquence hybride d'ARN pour produire le polypeptide hybride.
- 35 11. Procédé de préparation d'une enzyme hybride enzymatiquement active, comprenant une séquence hybride d'ADN telle que revendiquée dans l'une quelconque des revendications 1 à 9 et comprenant, en outre, la transcription de la séquence hybride d'ADN pour produire une séquence hybride d'ARN et la traduction de la séquence hybride d'ARN pour produire l'enzyme hybride enzymatiquement active.

40

45

50

55





FIG. - 2A

EP 0 208 491 B1



	HYBRID 11`							
	601	610	620	630	640	650	660	670
ess. nz3gene	601 CCTTGACTGGACCAAGCCGAAAATTAAAGCCGGCATTTACAAAATTCCGGGGCATCGGCCAA-GCGTGGGATTGGGAAGTAGACACGGAAACGGAAACTA							
ess. lich. gene	583 AACCGATTGGGACCAAGCTGGCATCTATAAGTTCAAAG-----GAAAGGCTGGGATTGGGAACCTTCCAAATGAAACGGCAACTA							
consensus	601 -----GA-TGGGACCA---CCGAAA-T-A-CCGGAT-TA-AA-TT-C-----AAA-GC-TGGGATTGGGAAGT---CA-GAAAACGG-AACTA							
HYBRID 5` - probe 6								
	701	710	720	730	740	750	760	770
ess. nz3gene	701 TGAATCTTAATGTATGCCGACCTTGATA-TGGATCATCCGGAAATGTCACCGAACCTGAAAAATTGGGGAAATGGTATGTCACACGAAACATT-G							
ess. lich. gene	683 TGAATTATTGATGCTGCCGACATCGATTAT-GACCATCCTGATGCTGGAGCAAAATTAGAGATGGGCACCTGGGATGCCATTGAACTGCAATT-GG							
consensus	701 TGA-TA-TT-ATG---GCCGAC-T-GAT---T-GA-CATCC-GA-GTCG---C-GA---T-AA-A---TGGG-A---TGGTATG-CAA---A-G-A---T---G							
HYBRID 5` - probe 6								
	801	810	820	830	840	850	860	870
ess. nz3gene	801 ATGGGGTCCGGGTTGATGCTGTCATGCTGTCAYACATTAAGTTCAAGTCTGGGATTTCTGCGGATTTCTGCGGATTTCTGCGGATTTCTGCGGAT							
ess. lich. gene	783 ACCGGTTCGGTTGATGCTGTCAYACATTAAGTTCAAGTCTGGGATTTCTGCGGATTTCTGCGGATTTCTGCGGATTTCTGCGGATTTCTGCGGAT							
consensus	801 A-GG-TTCCG-CTTGATGCTGTCAYACATTAAGTTCA-ATTA-TT---TTTTT-C-GATTGG-T-----ATGT---G---C-A-AC-GG-AAG---T-TTAC-GT							
HYBRID 5` - probe 7								
	901	910	920	930	940	950	960	970
ess. nz3gene	901 CGGGGATATTGGAGCTGACATCAAAGGGGAAATTGATAATTACATTAGAAAACGAAAGTCTGGGCGGCTGGAAACAACTATTGAAACAAAATT							
ess. lich. gene	883 AGCTGATATTGGAGATGACTTGGGGGGCTATGATAATGAGGAAACGTTGGGCGGCTGGAAACAAATTTAAATCAT-TCAGTGTGACGTGCCGCTTCAATTATCGTT							
consensus	901 -G-GATATTGG---ATGAC-T---C-G-TG-A-AA-TA---T-A---AAAACAAA---A-----T-TC-TGTTGA-G---CCG-1-CA---A-A-TT							
HYBRID 5` - probe 8								
	1001	1010	1020	1030	1040	1050	1060	1070
ess. nz3gene	1001 TTATACTGCTTCAAATCGGGGGCGAAATTGATAATGAGCAGCTTAATGAAATACTCTGATGAACTGCTTAACTCGGCGCTCACTTCGTTGAT							
ess. lich. gene	983 CCATGCTGCGATCGACACAGGGAGGGGGCTATGATAATGAGGAAATTTGCTGAACTGCTTAACTCGGCGCTTACGTTGAAATCGGTTACATTGTCGAT							
consensus	1001 --AT-CTGC-TC-A-A---GGG-GGGC---T-TGATATGAG-A---TT---TGAACTGAC---TAC---TC-T---A-CA-CCG-----C-GT-AC-TT-GT-GAT							
HYBRID 5` - probe 8								
	1101	1110	1120	1130	1140	1150	1160	1170
ess. nz3gene	1101 AATCATGACACGGAAACCGGCGCAAGGGCTGACCATGGGTCACTGGCTTAAGCTTAACCTGGGAGGAAGGATACC							
ess. lich. gene	1083 AACCATGATACACAGGGGGCGCAATGCTGAGTCGACTGCTGGCTCAACATGGTTAACATGGCTTACGTTGAACTCTGGATACC							
consensus	1101 AA-CATGA-AC---A-CC-GG-CAA-CGCT---GTC-A---CATGGT-T-AA-CCG-T-GCTTACGCG-TTATCT-AC---GG-A----GGATACC							

FIG. - 2B

	probe 9							
ess. nz3gene	1201	1210	1220	1230	1240	1250	1260	1270
ess. lich. gene	1201	CTTGGCTCTTTATGACTAT-TATGGCATTCG---ACAAT-ATAAC-----ATTCCTTCAC-TGAAAAAGCAAAAATUGATCGGCTCCATCGGGCGC						1290
consensus	1183	CTCAGGTTCTACGGGAT-AATGTAACGGGAGCAAGGAACTCCAGCGCAAATTGAAACACAAAATGAAACATCTAAAGCGGAA						1300
ess. nz3gene	1301	1310	1320	1330	1340	1350	1360	1370
ess. lich. gene	1283	AAACAGATATGCCTACGGGAGCACAGGATGATTATTCGACACCATGACATTGTCGGCTGACAAAGGGAAGGGACACGTGGTGC						1390
consensus	1301	A---A-TATGC-TA-GGA-C-CA-CATGATTAT-T-GA-CAC---GACAT--TCGG-TGGACAAAGGGAAGGC---AC-----CA---TC-GG--TGG						1400
ess. nz3gene	1401	1410	1420	1430	1440	1450	1460	1470
ess. lich. gene	1383	CGGCACATTAAACAGACGGACCUCGGTG---GGCAAAGGGAAATGGTATGTCGGGCCGGAAAACCGGTGAGACATGGC---ATGACATTACGGAAACCGTTCG						1490
consensus	1401	C-GCA-T-AT-AC-GA-GG-CC-GG-G---GCAA---GA---GTA-GT-GGC---CA-A-CGC---GA-A---TG---ATGAC-TTACGG-AAACCG-----						1500
ess. nz3gene	1501	1510	1520	1530	1540	1550	1560	1570
ess. lich. gene	1493	GACACCGTCAACATCAACAGTGGATGGGGAAATTCAAAGTCATTGGGGTTTCGGGTTCTAGAAAACCGGTCTACTATCG						1590
consensus	1501	GA---C-GT---CATCAA---GAGCGGGTGGAGGTTCAACGTAACGGGTTCAATTATGGTCAAAGATAAG						1600
ess. nz3gene	1601	1610	1620	1630	1640	1650	1660	1670
consensus	1601	CTTGGCCGATCACAAACCCGACCGTGGACTGGTGAATTGTCGGTTGGACCGAACCGAACGGTTGGCATGGCCTTGA						1690
consensus	1601	-----						1700

NZ3 is *B. sterothermophilus*lich is *B. licheniformis*

FIG. - 2C





FIG. - 3A

**FIG.-3B**




FIG. - 4

PROTEIN HOMOLOGY = 542	ep1.nz3	ep1.b.lich	consensus	1	10	20	30	40	50	HYBRID 4-
				1	VLTTFHRJJ-I-RKGWVFLLAFLWLTASLFCPTGQQPAKAAAPNGTMMQYFEWY					
				12	M-KQQKR-LYARLLTLFLALIFLLP					
				1	--R-----LL--	--P-----A-A--	--P-----A-A--	--P-----A-A--	--P-----A-A--	
				51	60	70	80	90	100	
				51	LPDDGTLWTKVANEANNLSSLGITALWLPPAYKGTTSRSRVGTYGYDLYDL					
				48	MPNDGQHWIKRLQNDSDAYLAEHGITAIVIPPAYKGTTSQADVGYYGAYDLYDL					
				51	-P-DG--W---N---L---GITA-W-PPAYKGTTS--DVGYYG-YDLYDL					
				101	-HYBRID 6	110	120	130	140	150
				101	GEFNQKGTIVRTKYGTTKAQYLQAIQAAHAAGMQVYADWVFDHKGGADGTEW					
				98	GEFHDKGTIVRTKYGTTKGELOSAIKSLHSRDINVYGDVVINHKGGADATED					
				101	GEF-QKGTIVRTKYGTTK-----AI-----H-----H-----VY-DVV--HKGGAD-TE-					
				151	160	170	180	190	200	
				151	VDAVEVNPSDRNQEISGTYQIQAUTKFDFNGRGNTYSSFKVRWYHFDGVD					
				148	VTAVEVDPADRNRYVISGEHLIKAWTHFHFPGRGSTYSDFKWHWYHFDGTD					
				151	V-AVEV-P-DRN--ISG--I-AWT-F-F-GRG-TYS-FKW-WYHF DG-D					
				201	210	220	230	240	250	
				201	WDESRKL SRIYKFRIGKAWDWEVDTENGNYDYLMYADLDMHDPEVYTEL					
				198	WDESRKL NRIYKFGQK--AWDWEVSNENGNYDYLMLADIDYDHDVAAEI					
				201	WDESRKL -RIYKF-G---AWDWEV--ENGNYDYL-AD-D-DHP-V--E-					
				251	HYBRID D-	270	280	290	300	
				251	KNWGKWWVNTTNIDGFRLDÄVQHIKFSFFPDWLSYVRSQQTGKPLFTVGEY					
				248	KRWGTVYANELQLDGFRLDÄVQHIKFSFLRDVNVHVRAKTGKEMFTVAEY					
				251	K-WG-WY-N---DGFRLDÄVQHIKFSF--DW---VR--TGK--FTV-EY					



FIG.-6A

ep1.nz3	301	310	320	330	340	350
ep1.b.lich	WSYDINKLHNYITKINGTMSLF DAPLHNKF YTASKSGGAF DMSTLMNNTL					
consensus	WQNDLGALENYLNKTNF NHNSVFDVPLHYQFHAASTQQGGYDMRKLLNGTV					
ep1.nz3	298	301	310	320	330	340
ep1.b.lich	W--D---L-NY---KTN---S-FD-PLH--F--AS--GG--DM--L-N-T-					
consensus	----P---VTFVDNHDT-PGQ-L-S-V--WFKPLAYAFILTR--GYP-VF					
ep1.nz3	351	360	370	380	390	400
ep1.b.lich	MKDQAPTTLAVTFVDNHDTEPGQALQSWSVDPWFKPLAYAFILTRQEGYPCVF					
consensus	348 VFKHPLKSVTFVDNHDQTQGQSLESTVQTWFKPLAYAFILTRESGYPQVF					
ep1.nz3	351	360	370	380	390	400
ep1.b.lich	YGDYYGIPQY---NIPSLKSKIDPLLIARRDYAYGTQHQHDYLDHSDDIIGWT					
consensus	398 YGDMYGTKGDSQREIPALKHKIEPILKARKQYAYGAQHHDYFDHHDIVGWT					
ep1.nz3	401	410	420	430	440	450
ep1.b.lich	YGD-YG-----IP-LK-KI-P-L-AR--YAYG-QHDY-DH-DI-GWT					
consensus	401 YGD-YG-----IP-LK-KI-P-L-AR--YAYG-QHDY-DH-DI-GWT					
ep1.nz3	451	460	470	480	490	500
ep1.b.lich	REGVTEKPGSGLAALITDGPGGSKWMYYVGKQHAGKVFYDLTGNRSDTVTI					
consensus	448 REGDTSVANSGLAALITDGPGGQSECMASAGKTRET-WHDITGNRSEPVVI					
ep1.nz3	451	460	470	480	490	500
ep1.b.lich	REG-T----SGLAALITDGPGG-----D-TGNRS--V-I					
consensus	451 REG-T----SGLAALITDGPGG-----D-TGNRS--V-I					
ep1.nz3	501	510	520	530	540	550
ep1.b.lich	NSQGWGEFKVNGGSVSVWPRKTTVTSTIAWPITTRPWTGEFVRWTEPRLV					
consensus	498 NSEGWESEFTVNGGSVSIVYQQR					
ep1.nz3	501	510	520	530	540	550
ep1.b.lich	NS-GW--F-VNGGSVS--V-R-----					
consensus	501 NS-GW--F-VNGGSVS--V-R-----					
ep1.nz3	551	560	570	580	590	600
ep1.b.lich	AMP					
consensus	551 ---					

CROSSOVER LOCI IN PROTEINS ENCODED BY ALPHA AMYLASE GENES OF HYBRIDS 4, 6, AND D (BOXED)

nz3 is *B. stearothermophilus*
lich is *B. licheniformis*

FIG. - 6B

**FIG. -5****FIG. -7**

